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ABSTRACT
THE IMPACT OF PSYCHOSOCIAL TREATMENT ON MEDICATION
TREATMENT
FOR OPIOID USE DISORDER
MAY 2020
TARA MARIOLIS, B.S., HARTWICK COLLEGE
M.S., BOSTON UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Lisa Chiodo

In 2017, more than 70,000 people in the United States died due to drug overdoses;
of that number, approximately 68% involved prescription or illicit opioids (CDC, 2019).
Presently, insurance companies and physicians require all opioid use disorder (OUD)
patients to receive counseling during medication treatment for OUD, despite the lack of
evidence it is necessary for all patients. This requirement restricts access and creates
hardship for those who may benefit from medication alone. In an effort to inform policy
and improve quality of treatment, this nonexperimental, correlational study examined the
relationship between individual counseling status and treatment outcomes in patients
receiving medication treatment for OUD. Treatment outcome variables (treatment
utilization, medication use, and opioid use) were extracted from the electronic health
records of 11,551 adults who received treatment between January 2016 and January
2018. The impact of individual counseling on outcome variables was examined while
controlling for confounding variables (gender, age, race, ethnicity, PTSD/trauma,
anxiety, and criminal justice involvement). Bivariate analyses suggested women in OUD
vii

treatment were prone to have experienced PTSD/trauma and anxiety, while males were
more likely to have CJS involvement. Women were more often retained in care and were
in treatment for longer periods of time than males. In addition, older patients used OUD
medication more often than younger patients; however, older patients were also more
prone to use benzodiazepines and alcohol. Multivariate analyses revealed patients with
increased rates of treatment utilization were more likely to utilize medication treatment
and demonstrate reduced opioid use. In addition, higher rates of treatment utilization
were related to reduced opioid use. Patients with more frequent interruptions in OUD
treatment more often tested positive for opioids. This study revealed very little evidence
that counseling during OUD treatment had a positive impact on treatment utilization. Yet,
it found no evidence that counseling while active in treatment had an impact on
medication utilization or opioid use. Although counseling may have some benefit for
some patients in OUD treatment, these findings do not support mandating counseling
during OUD treatment.
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CHAPTER 1
INTRODUCTION
Background of the Problem
The misuse of opioids is a serious public health crisis in the United States and
around the world. Its impact is both devastating and far-reaching, affecting nearly every
individual, community, city, and state across the country. In the U.S., an average of 115
people die each day due to overdoses on opioids (Centers for Disease Control [CDC],
2017b; National Institute of Drug Abuse [NIDA], 2018a). It is imperative to identify
effective and accessible treatments, and quickly put them into practice. While many
treatments are already in use, progress in halting the opioid crisis has been slow.
Research is needed to determine advantages of current pharmacotherapies and
psychosocial approaches, treatment combinations, and treatment settings, specifically
office-based primary care (Kampman & Jarvis, 2015).
The focus of this research study was to examine the relationship between
individual counseling status and several treatment outcomes in patients receiving
medication treatment for opioid use disorder (OUD). The outcome variables examined
included treatment utilization, medication utilization, opioid use and other substance use.
This relationship was examined while controlling for important potential confounding
variables (e.g., gender, age, race, ethnicity, PTSD/trauma, anxiety, and criminal justice
system (CJS) involvement).
Opioid Abuse and Opioid-Related Deaths
Addiction specialists, healthcare providers (HCPs), and opioid treatment
programs have been inundated due to the sharp rise in opioid abuse in the U.S. and
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worldwide. It is estimated that the prevalence of opioid use is .70% (32.4 million) of the
world population of adults (National Center for Health Statistics, 2015). In 2018, an
estimated 10.3 million persons aged 12 and older misused opioids. An estimated 9.9
million misused prescription opioids, and 808, 000 were heroin users (Substance Abuse
and Mental Health Services Administration [SAMHSA], 2019a). In 2017, more than
70,000 people died due to drug overdoses, making it a leading cause of death in the
United States. Of that number, approximately 68% involved prescription or illicit opioids
(CDC, 2019). To understand the scope of economic burden of prescription opioid
overdoses worldwide, Florence, Zhou, Luo, and Xu (2016) examined reports of fatal
prescription opioid overdoses from the National Survey of Drug Use and Health. They
found the financial cost due to fatal overdoses and abuse of prescription opioids to be an
estimated $78.5 billion. One third of this amount was due to increased healthcare and
substance abuse treatment costs.
The “Morbidity and Mortality Weekly Report” compiled by the CDC revealed
that, during 2017, 130 individuals died each day in the U.S. due to opioids (CDC, 2017b).
Drug overdose deaths from any opioid including heroin, prescription opioids, synthetic
opioids, and methadone rose from 16,849 in 1999 to 70,237 in 2017. Furthermore,
Muhuri, Gfroerer, and Davies (2013) found that among new users of heroin, three out of
four users reported their problem use began with medically prescribed opioids. Given the
scope and depth of opioid abuse and its consequences, it is essential to have evidencebased treatment approaches made widely accessible (American Society of Addiction
Medicine (ASAM), 2014).
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The Opioid Epidemic
The source of widespread opioid abuse in the U.S. is multifaceted. In the 1980s, a
poor-quality research study was disseminated that proposed several chronic pain
conditions could be treated with opioids (Portenoy & Foley, 1986). A large
pharmaceutical company then developed a highly addictive, opioid-based pain
medication (OxyContin) and funded a large educational campaign targeting physicians,
which put forth that chronic pain due to a wide range of serious health problems could be
safely managed with long-term opioid treatment (Kolodny et al., 2015).
At around the same time, the Joint Commission of the Accreditation of Healthcare
Organizations (JCAHO) identified a pattern by physicians of inadequately treating pain
in patients (Berry & Dahl, 2000). The JCAHO actively encouraged physicians to be more
aggressive in treating pain. Assuming little risk of harm, physicians began prescribing
opioids at increased rates. This led to widespread access and proliferation of opioids,
heightening abuse among patients, even for those who took the medication as instructed.
The result was pervasive opioid abuse and an opioid epidemic.
Several measures were instituted to address the problem. In 2017, the President’s
Commission on Combating Addiction and the Opioid Crisis put forth several
recommendations for limiting access, and increasing funding for prevention, treatment
and research (President's Commission, 2017). Notably, the report recommended that
congress and the federal government provide funding to the National Institute of Drug
Abuse (NIDA), and the National Institute of Mental Health (NIMH) for a review of
existing research programs, and for additional research on the prevention and treatment
of opioid abuse.
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In addition, the American Society of Addiction Medicine (ASAM), in a recent
publication of “National Practice Guidelines for Use of Medications in the Treatment of
Opioid Use Disorder,” identified several research objectives on the application of
psychosocial treatments (Kampman & Jarvis, 2015, p. 23). Included among these
objectives are (a) identifying comparative advantages of specific psychosocial treatments;
(b) determining the effectiveness of psychosocial treatment in combination with specific
pharmacotherapies; and (c) identifying psychosocial treatments appropriate for addition
to buprenorphine or naltrexone that can be delivered in primary care settings (Kampman
& Jarvis, 2015, p. 39).
Treatments for Opioid Use Disorder
Treatments available for opioid use disorder (OUD) include pharmacotherapies
and psychosocial treatments. Medications include methadone (mu agonist) and
buprenorphine (partial mu agonist), which are used for treatment and withdrawal
management. Naltrexone (antagonist) is used for relapse prevention, and naloxone
(antagonist) for treatment of overdose (Kampman & Jarvis, 2015). It is currently
recommended that psychosocial treatments such as cognitive behavioral therapy and
coping skills training, community reinforcement approaches, contingency management,
and motivational interviewing be added to medication treatment (NIDA, 2018a, 2018b).
Although medications may be used as a stand-alone treatment, some individuals benefit
from psychosocial treatments that assist with engagement in treatment, abstinence, and
prevention of relapse (Dugosh et al., 2016). Successful engagement in treatment has been
shown to reduce illicit drug use, improve brain function, treatment adherence, health, and
overall functioning (NIDA, 2018a).
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Medication Treatment
The four medications most commonly used to treat OUD are methadone (MET),
buprenorphine (BUP), naloxone (NX), and naltrexone (NTX; Fullerton et al., 2014; Lee
et al., 2018; NIDA, 2017, 2018b SAMHSA, 2018a; Thomas et al., 2014). BUP acts as an
agonist at the mu opioid receptor and an antagonist at the kappa receptor (SAMHSA,
2018a). It acts by lowering risk of abuse and physical dependence, has few withdrawal
symptoms, possesses a ceiling effect at high doses, and has improved safety over opioid
full agonists (Lutfy & Cowan, 2004). It is often combined with NX, which acts by
blocking opioid receptors, thereby blocking opiates and reducing the potential for abuse.
BUP and BUP combined with NX are delivered in office-based settings, substance abuse
clinics, and treatment centers. BUP is an effective and widely used medication for the
treatment of OUD.
Methadone (MET) is a potent synthetic opioid analgesic that is structurally unique
among other opioid classes. It has properties similar to morphine; however, it is long
acting. It eliminates withdrawal symptoms and reduces cravings by acting on the same
brain targets as heroin and morphine (NIDA, 2018a). It has been used successfully to
treat heroin dependence for over 40 years, although it must be dispensed at approved
treatment centers (NIDA, 2018a).
Naltrexone (NTX) is an opioid antagonist that counters the effects of opioids and
reduces cravings for opioid-based drugs. If opioids are taken during treatment with NTX,
withdrawal symptoms ensue. Its use has been limited due to poor adherence and
tolerability, although it has demonstrated effectiveness when combined with psychosocial
treatments such as contingency management (DeFulio et al., 2012; Everly et al., 2011;
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NIDA, 2018a; Preston et al., 1999). The utilization of medications such as MET, BUP,
NX, and NTX has significantly improved opioid use treatment in recent years.
Psychosocial Treatments
While medications are highly effective in treating OUD, the addition of
psychosocial treatment has demonstrated mixed results (W. Ling, Hillhouse, Ang,
Jenkins, & Fahey, 2013; Otto et al., 2014; Stein et al., 2015). Psychologically based
therapies are thought to assist patients by modifying an individual’s thinking and
behavior patterns in relation to opioid use, improving health-promoting skills, adherence
to treatment, and relapse prevention (NIDA, 2018c). Approaches include medical
management, individual, group and family therapy, cognitive behavioral therapy,
contingency management, and motivational interviewing (Brooner et al., 2007; DeFulio
et al., 2012; Fiellin et al., 2014; NIDA, 2016). While not considered a psychosocial
treatment, peer-support is an adjunctive approach that is effective for some individuals
(Kampman & Jarvis, 2015, p. 38). Treatment approaches can include 12-step programs
such as Narcotics Anonymous (NA), Self-Management, and Recovery Therapy
(SMART), among others. Depending on the type of treatment required to meet treatment
goals, psychosocial treatments are available at hospitals, outpatient clinics, and
residential settings.
Significance of the Study
Extensive research evidence suggests that medication treatment for OUD is
highly effective (Dennis et al., 2014; Fiellin et al., 2008, 2014; Gunderson, Hjelmström,
& Sumner, 2015; W. Ling et al., 2010, 2013; Mattick, Breen, Kimber, & Davoli, 2014;
Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016). Currently, providers and
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insurance companies require patients to attend counseling during OUD treatment despite
lack of evidence that it is necessary for all patients (Fiellin et al., 2006, 2013; W. Ling et
al., 2013; Weiss et al., 2011). This requirement restricts access to care and creates
hardship for those who may benefit from medication treatment alone. Counseling may
not be necessary for patients who benefit from medication as a standalone treatment. The
results of the present study will better inform policy, reduce treatment burden for
patients, and improve the quality of patient care.
Purpose of the Study
The focus of this research study was to examine the relationship between
individual counseling status and outcome variables in patients receiving medication
treatment for OUD. The outcome variables examined included treatment utilization
(maintenance visits, random maintenance visits, rescheduled visits, other encounters, care
interruptions, no-show visits, total time in care, and time since last visit), medication
utilization, opioid and other substance use, and treatment retention. The impact on
outcome variables was examined while controlling for important confounding variables
(e.g., gender, age, race, ethnicity, PTSD/trauma, anxiety, and CJS involvement).
Aims and Hypotheses
Aim 1. What is the relationship between treatment utilization, medication utilization, and
opioid use in a sample of individuals with opioid use disorder receiving medication
treatment?
H1a: Patients with a higher rate of random maintenance visit compliance will have
increased medication utilization.
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H1b: Patients with a higher rate of maintenance visit compliance will have increased
medication utilization.
H1c: Patients with a lower rate of “no show” visits will have increased medication
utilization.
H1d: Patients with longer total time in care will have increased medication utilization.
H1e: Patients with a lower rate of rescheduled visits will have increased medication
utilization.
H1f: Patients with a lower rate of other encounters will have increased medication
utilization.
H1g: Patients with a lower rate of care interruptions will have increased medication
utilization.
H1h: Patients with less time since the last visit will have increased medication
utilization.
H1i: Patients with a higher rate of random maintenance visit compliance will have
decreased opioid use.
H1j: Patients with a higher rate of maintenance visit compliance will have decreased
opioid use.
H1k: Patients with a lower rate of “no show” visits will have decreased opioid use.
H1l: Patients with longer total time in care will have decreased opioid use.
H1m: Patients with a lower rate of rescheduled visits will have decreased opioid use.
H1n: Patients with a lower rate of other encounters will have decreased opioid use.
H1o: Patients with a lower rate of care interruptions will have decreased opioid use.
H1p: Patients with less time since the last visit will have decreased opioid use.
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H1q: Patients with increased medication utilization will have decreased opioid use.
Aim 2. Determine if medication utilization mediates the relationship between treatment
utilization and opioid use in patients receiving medication treatment.
H2a: Medication utilization will mediate the relationship between rate of random
maintenance visit compliance and opioid use.
H2b: Medication utilization will mediate the relationship between rate of maintenance
visit compliance and opioid use.
H2c: Medication utilization will mediate the relationship between rate of “no show”
visits and opioid use.
H2d: Medication utilization will mediate the relationship between total time in care
and opioid use.
H2e: Medication utilization will mediate the relationship between rate of rescheduled
visits and opioid use.
H2f: Medication utilization will mediate the relationship between rate of other
encounters and opioid use.
H2g: Medication utilization will mediate the relationship between rate of care
interruptions and opioid use.
H2h: Medication utilization will mediate the relationship between time since the last
visit and opioid use.
Aim 3. Examine the impact of current and prior counseling on treatment utilization,
medication utilization, substance use, and treatment retention.
H3a: There will be no difference in rate of random maintenance visit compliance
between patients who are currently in counseling and those who are not.
9

H3b: There will be no difference in rate of random maintenance visit compliance
between patients who have previously been in counseling and those who are not.
H3c: There will be no difference in rate of maintenance visit compliance between
patients who are currently in counseling and those who are not.
H3d: There will be no difference in rate of maintenance visit compliance between
patients who have previously been in counseling and those who are not.
H3e: There will be no difference in rate of “no show” visits between patients who are
currently in counseling and those who are not.
H3f: There will be no difference in rate of “no show” visits between patients who have
previously been in counseling and those who are not.
H3g: There will be no difference in total time in care between patients who are
currently in counseling and those who are not.
H3h: There will be no difference in total time in care between patients who have
previously been in counseling and those who are not.
H3i: There will be no difference in rate of rescheduled visits between patients who are
currently in counseling and those who are not.
H3j: There will be no difference in rate of rescheduled visits between patients who
have previously been in counseling and those who are not.
H3k: There will be no difference in rate of other encounters between patients who are
currently in counseling and those who are not.
H3l: There will be no difference in rate of other encounters between patients who have
previously been in counseling and those who are not.
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H3m: There will be no difference in rate of care interruptions between patients who
are currently in counseling and those who are not.
H3n: There will be no difference in rate of care interruptions between patients who
have previously been in counseling and those who are not.
H3o: There will be no difference in time since last visit between patients who are
currently in counseling and those who are not.
H3p: There will be no difference in time since last visit between patients who have
previously been in counseling and those who are not.
H3q: There will be no difference in medication utilization between patients who are
currently in counseling and those who are not.
H3r: There will be no difference in medication utilization between patients who have
previously been in counseling and those who are not.
H3s: There will be no difference in opioid use between patients who are currently in
counseling and those who are not.
H3t: There will be no difference in opioid use between patients who have previously
been in counseling and those who are not.
H3u: There will be no difference in treatment retention between patients who are
currently in counseling and those who are not.
H3v: There will be no difference in treatment retention between patients who have
previously been in counseling and those who are not.
Aim 4. To examine the comparative effectiveness of type of psychosocial treatment on
medication utilization, treatment utilization, and opioid use in patients receiving
medication treatment.
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H4a: There will be no difference in rate of random maintenance visit compliance
across different types of psychosocial treatment.
H4b: There will be no difference in rate of maintenance visit compliance across
different types of psychosocial treatment.
H4c: There will be no difference in rate of “no show” visits across different types of
psychosocial treatment.
H4d: There will be no difference in total time in care across different types of
psychosocial treatment.
H4e: There will be no difference in rate of rescheduled visits across different types of
psychosocial treatment.
H4f: There will be no difference in rate of other encounters across different types of
psychosocial treatment.
H4g: There will be no difference in rate of care interruption across different types of
psychosocial treatment.
H4h: There will be no difference in time since the last visit across different types of
psychosocial treatment.
H4i: There will be no difference in medication utilization across different types of
psychosocial treatment.
H4j: There will be no difference in opioid use across different types of psychosocial
treatment.
Summary
The rise in OUD and opioid-related deaths is an urgent public health crisis in the
U.S. and around the world. Evidence suggests medication treatment is highly effective
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for OUD and its related health consequences. Little research has been done on the impact
of psychosocial treatments such as counseling on outcome variables for the treatment of
OUD. This is especially important given that most providers of medication treatment
require patients to receive psychosocial treatment despite lack of research demonstrating
its effectiveness. These study findings further advance our knowledge of effective
treatment for OUD.
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CHAPTER 2
THEORETICAL FRAMEWORK AND REVIEW OF LITERATURE
This chapter describes the etiology of OUD, the origin, recent history and impact
of the opioid epidemic, and current treatment approaches from the perspective that OUD
is a chronic brain disease requiring long-term treatment and management. Additionally,
the theoretical framework underpinning the study, the Neuman Systems Model, key
definitions, and a review of the literature are presented.
Opioid Use Disorder
OUD is a chronic and debilitating disease, which when left untreated may result
in significant health problems, physiological dependence, overdose, and death. Opioids
are a class of medications available via prescription and in the form of heroin, an illicit
opioid (NIDA, 2018a). Opioids come in a variety of forms that are similar in chemical
composition. Opioids interact with opioid receptors in the body, resulting in many
physiologic changes including the following: (a) depression of breathing due to
neurochemical effect on the brainstem, (b) heightened sense of pleasure due to the effects
on the limbic system, and (c) reduced pain reception throughout the body (NIDA, 2018d).
Opioids are generally safe when used as prescribed; however, they are widely
misused and abused. Even when taken as directed, physiological dependence may occur,
thereby increasing the risk of overdose and death (NIDA, 2018b). The complex nature of
the disorder, reduced access to treatment, combined with a rapidly growing opioid
epidemic, has created a public health crisis in the United States and around the world
(Volkow et al., 2018). Furthermore, the stigma associated with OUD is longstanding and
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continues to present barriers to treatment, reducing access, and slowing the development
of effective treatments.
How it is that some individuals are able to avoid the ravages of opioid abuse
while others are not, has baffled healthcare professionals and addiction specialists. While
far from clear, the answer very likely lies in the complex nature of an individual’s
biology, cognition, personality, life experience, and ability to utilize supports. For
example, evidence exists that persons with mental health problems such as anxiety and
depression face a higher risk of developing OUD (Barry et al., 2016; Rosic et al., 2017;
Savant et al., 2013). Additionally, persons with a tendency toward impulsivity find it
more difficult to resist using the drug (Baldacchino, Balfour, & Matthews, 2015;
Tolomeo, Gray, Matthews, Steele, & Baldacchino, 2016). Finally, one’s access to the
drug, developmental stage, and traumatic experiences may place an individual at further
risk of OUD (Kumar, Stowe, Han, & Mancino, 2016; Stein et al., 2017).
The results of extensive biological research have shed light on the brain’s role in
perpetuating opioid abuse. For instance, there is evidence that an individual’s
neurobiological makeup may set the stage for genetic vulnerability for abusing opioids.
Genetics also may play a role in one’s physiological response to opioids, and long-term
abuse of opioids may affect the delicate balance of neurotransmitters in the brain. The
interaction of environmental and social factors, as well as a biological predisposition to
vulnerable brain pathways leading to opioid abuse, may also produce cravings and
episodes of relapse years after an individual is no longer dependent (Kosten & George,
2002). Moreover, brain abnormalities that result from chronic use of opioids can lead to
physiological changes and consequences that are wide-ranging and long-lasting (Kosten

15

& George, 2002). Understanding the complex causes and effects of OUD permits
clinicians and researchers to identify predictors, develop effective treatments, and quickly
put them into practice in order to improve patient outcomes.
Significance of the Opioid Epidemic
The opioid epidemic has become a major public health problem in the U.S. and
around the world. Globally, it is estimated that 15 million people suffer from opioid
dependence and that 69,000 persons die each year from opioid overdose (World Health
Organization, 2014). In the U.S., drug overdoses have tripled in the last 15 years (Rudd,
Seth, David, & Scholl, 2016). In 2015 alone, drug overdoses accounted for 52,404 deaths
in the U.S., and 33,091 (63.1%) were due to opioids. Further, a study by Florence et al.
(2016) suggests that overdoses of prescription opioids have resulted in an economic
burden to the U.S. of $78.5 billion.
Additionally, the degree to which the opioid epidemic has escalated the spread of
infectious diseases underscores the health consequences of OUD. For example, from
2004–2014, there was an increased rates of hepatitis C (400% among 18–29 year olds
and 325% among 30–39 year olds) and hepatitis B (20, 000 new cases in the U.S. among
persons who inject drugs; CDC, 2017a). The rates of HIV, endocarditis, epidural abscess,
and other conditions have also increased among persons who inject drugs (Department of
Health and Human Services, 2017).
The cause of the most recent opioid epidemic is complex. In part, it arose from
the common practice of physicians overprescribing the medication. In the 1990s, the
Joint Commission of the Accreditation of Hospitals admonished physicians and other
professional groups for inadequately treating pain in patients with a number of medical
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conditions. As a result, physicians began prescribing opioids in abundance, which led to
increased access and heightened risk for addiction, even among patients who took the
medication as prescribed. Furthermore, increased availability of opioids in homes placed
vulnerable persons such as children and adolescents at risk for addiction and opioidrelated deaths.
While the widespread overuse of opioids has occurred in the past, factors
converging to create the most recent epidemic began in the 1980s. Around that time a
low-quality paper with little scientific merit was disseminated proposing that chronic pain
conditions could be safely managed over many months or even years with opioids
(Portenoy & Foley, 1986). Within a few years, a large pharmaceutical company had not
only developed a highly addictive opioid-based pain medication, (OxyContin) but also
funded a large educational campaign that targeted physicians and proposed that chronic
pain, due to a variety of medical conditions, could be safely treated with the long-term
opioid treatment (Kolodny et al., 2015). Around the same time, a recommendation by the
Joint Commission of the Accreditation of Hospitals suggested that pain was largely
undertreated by physicians. The commission actively encouraged physicians to be more
aggressive in treating pain, especially in view of the recent “so-called” evidence
demonstrating the safety of opioids. Physicians, who had been reluctant to prescribe
opioids in the past, began prescribing them at an increased rate, all the while believing
that there was little-to-no risk of harm to patients.
Theoretical Framework
Given the complexity of OUD, it is difficult to understand from the perspective of
a single theory or conceptual framework. The examination of several viewpoints may be
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necessary in order to grasp the complex nature and progression of OUD. Examining it
from the viewpoint that it is both a neurobiological illness and a chronic disease requiring
ongoing management by healthcare providers and clients over long periods provides a
useful framework on which the present study was based. Additionally, the Neuman
Systems Model provides a theoretical framework for understanding OUD in the context of
multiple contributing factors.
Neurobiology of Opioid Use Disorder
One may better understand OUD when taking into account the role the brain plays
in perpetuating the use of opioids. The brain contains many neurons and synapses that
generate neurotransmitters. Neurotransmitters shape one’s thinking and behavior, respond
to stimuli, and maintain all vital functions in the body (NIDA, 2016b). In addition, they
permit neurons to communicate signals to other nearby neurons. In order to maintain
essential bodily functions, the action of neurotransmitters in the brain must remain in
balance (Halter, 2014). Many people continue to use opioids due to their effect on the
“reward” center of the brain. The euphoria one experiences from using opioids is thought
to be due to stimulation of the reward system with an excess of dopamine (NIDA,
2016b). Normally, this action mobilizes an individual to continue behaviors needed in
order to survive, such as eating and experiencing pleasure during contact with loved ones
(Hazeldon Betty Ford Foundation, 2015). That euphoria experienced after using opioids
is what prompts individuals to use the drug repeatedly. Eventually, tolerance develops, as
well as the need to take more and more of the drug to gain that sense of “high.”
Moreover, the long-term effects of using opioids cause changes in the executive
function of the brain, affecting judgment, decision-making, and responses to stress (Liu et
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al., 2011). Prolonged use of opioids leading to physiologic dependence results in
compulsive drug-seeking at any cost (Kreek et al., 2012). The results of a study by
Upadhyay et al. (2010) found that among prescription opioid-dependent subjects, notable
changes occurred in axonal pathways to the amygdala and functional connectivity to
amygdala subdivisions. The researchers found that the longer the duration of opioid
exposure, the greater the changes in functional connectivity of the brain. The findings
suggest that prolonged opioid exposure is associated with changes in the brain
responsible for the regulation of affect, control of impulses, and motivation (Upadhyay et
al., 2010). Furthermore, the extent to which brain function is altered by opioid abuse
itself, may be due to a genetic predisposition for the development of OUD that
necessitates long-term treatment and management.
Opioid Abuse as a Chronic Brain Disease
In 2011, the American Society of Addiction Medicine (ASAM) put forth a new
definition of addiction. The definition resulted from a concerted process involving more
than 80 experts in the field of addiction from across the United States. The definition
describes addiction as a primary disease, not the result of behavioral or emotional
problems. OUD is recognized by the organization as a chronic illness much like diabetes
or heart disease. It is presently identified as a chronic brain disease with periods of
relapse and remission that cannot be cured (but rather managed), and should be treated as
such (ASAM, 2014).
“Addiction is a primary, chronic disease of brain reward, motivation, memory and
related circuitry. Dysfunction in these circuits leads to characteristic biological,
psychological, social and spiritual manifestations. This is reflected in an
individual pathologically pursuing reward and/or relief by substance use and other
behaviors. Without treatment or engagement in recovery activities, addiction is
progressive and can result in disability or premature death,” (ASAM, 2014, p. 1).
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According to the ASAM (2014), OUD is a chronic brain disease affecting the
reward system, motivation, memory, and related neurophysiology. Abuse of opioids over
time leads to disturbances in neurophysiology resulting in distinct behavioral,
psychological, and social symptoms. In order to gain relief, an individual compulsively
seeks opioids and engages in behaviors in order to relieve the symptoms. Without
treatment and recovery, opioid abuse is progressive and may lead to death (ASAM,
2011b).
Much like other chronic diseases, OUD presents with periods of relapse and
remission, and has no cure. As with any chronic illness, treatment is aimed at effectively
coping with symptoms over time. Managing OUD requires preventative, patient-oriented,
and individualized continuing care. According to the ASAM (2014), optimal treatment of
OUD is coordinated and provided in three phases: identification, stabilization, and
patient-self management. A wide range of treatments are available in a comprehensive
plan of care, including commonly used medications: MET, BUP or BUP/NX and NTX.
The medications can be used at all phases of treatment, are highly effective and often
underutilized (ASAM, 2013). While most chronic diseases require medications for longterm management, persons requiring medications for OUD, are subject to numerous
barriers in receiving pharmacological treatment. Barriers include, but are not limited to,
regulatory and insurance restrictions on prescribing practices, dosage, access, treatment
duration, a complex system of prior-authorization requirements, and step-therapy
treatment approaches. In order to provide high-quality evidence-based treatment for
OUD, the elimination of longstanding barriers to treatment is necessary.
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Proposing that OUD is a chronic disease as opposed to a problem rooted in
behavior alone has many advantages. First, it explains the compulsive nature of opioid
abuse despite consequences to the individual, family members, and society. The behavior
is a manifestation of a disease that involves many parts of the brain. Second, it suggests
that neurobiology plays a significant role in an individual’s vulnerability and likelihood
to develop the disease. Furthermore, treatment approaches are now available that target
the brain itself, as well as the changes that have occurred due to long-term opioid abuse.
Finally, viewing OUD as a chronic disease such as diabetes or heart disease implies that
it requires ongoing management and treatment, perhaps, over a lifetime (ASAM, 2011a).
The Neuman Systems Model
The Neuman Systems Model (NSM) was originally derived from general systems
theory and is based on the principle that individuals are open systems interacting with one
another and the environment (Neuman, 1982). Neuman synthesized knowledge from
several disciplines in order to develop the theory but incorporated many of her own ideas
from her clinical work in mental health nursing. The model draws a number of ideas from
Gestalt Theory (Perls, 1973), which defines homeostasis as an important process by
which an organism maintains its equilibrium and well-being. In order to maintain health,
an organism must continually adapt to its environment. At any time, the system may
become stressed, which threatens the balance and stability of the organism; therefore
adjustment to stressors is a continuous and active process. According to Neuman, in the
event that the adjustment process fails during an attempt to stabilize an organism during a
period of increased stress, illness or death may result (Marriner-Tomey & Alligood,
1998).
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The NSM views an individual as an open/permeable system that is continually
responding and adapting to stress from the environment. The variables that determine
successful adaption may be physiological, psychological, sociocultural, developmental,
and spiritual (Neuman & Fawcett, 2011). Neuman views individuals as possessing a core
structure that is safeguarded by lines of resistance. An individual’s level of health is
determined by well-functioning normal lines of defense (NLD; Neuman, 2011). Should
the NLD become overtaxed, a flexible line of defense (FLD) protects it. Stressors are one
of three kinds: intra-, inter-, and extrapersonal forces that exist in internal, external, and
created environments. In the event a stressor becomes too great and overtaxes the FLD,
the system goes into a state of disequilibrium, thereby becoming unstable (Neuman &
Fawcett, 2011). As this occurs, lines of resistance are activated, which causes the system
to move into a state of illness. If the system possesses adequate energy and support, it
will re-stabilize, and the NLD may be restored either to its original state or improved
from its previous state (Gonzalo, 2011).
Concepts Central to the Neuman Systems Model
The major concepts described are integral to the NSM. They include the
following: holistic approach, open system, process, feedback, negentropy, stability,
environment, client system, lines of defense, normal line of defense, flexible line of
defense, stressor, health, illness, prevention (as intervention at the primary, secondary,
and tertiary levels) and reconstitution (Alligood, 2014; Marriner-Tomey & Alligood,
1998; Neuman, 2011; Neuman & Fawcett, 2011).
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Holistic Approach
NSM is a dynamic, open, systems approach to nursing care of the client. The
model was developed as a unifying paradigm for defining problems, generating nursing
care and appreciating the client in interaction with the environment. An open system may
be a person, family, group, community or social problem (Neuman, 2011, pp. 327–329).
Because OUD disrupts many aspects of a client’s life experience, treatment approaches
must be holistic
Open System
A system in which there is a continuous flow of input, processes, output, and
feedback. Stress and responses to stress are components of an open system, which may be
a person, family, group, community, or social problem (Neuman, 2011, pp. 327–329). As
clients receive treatment for OUD, a continuous exchange of input and output occurs
from both the treatment and client systems.
Process
An open system exchanges energy, data, and elements in the environment and its
parts and uses available energy to maintain equilibrium or homeostasis (Neuman, 1995;
2011, p. 328). As an individual actively engages in treatment, their relationships, and
environment, a process occurs that results in an exchange of energy and information.
Feedback
Output from the system in the form of data, energy, or matter serves as future
input for corrective action to ensure change, enhancement, or equilibrium (Neuman,
2011, p. 327). Persons with OUD, as well as treatment providers, use feedback to
determine the extent to which treatment is relieving symptoms and disruptions.
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Negentropy
The function of energy conservation that assists a system to move toward stability
or wellness (Neuman, 1995; 2011, p. 328). According to Neuman, treatment providers
and clients must be mindful that energy conservation is necessary for the system to move
toward wellness.
Stability
A dynamic and desirable state of balance and equilibrium in which energy
exchange takes place without undue disruption of the system, enabling the system to
move toward optimum wellness (Neuman, 1995; 2011, p. 328). As disruptions due to
OUD resolve, the client moves toward balance, equilibrium, and stability.
Environment
According to Neuman, the environment is comprised of “internal and external
forces surrounding the client, influencing and being influenced by the client at any point
in time” (Neuman, 1995; 2011, p. 327). The environment may influence the progression
of OUD depending on internal and external stressors in an individual and in external
environments.
Client System
Comprised of five variables (physiological, psychological, sociocultural,
developmental, and spiritual), all of which interact with the environment (Neuman, 2011,
p. 327).
Lines of Resistance
A series of permeable rings surrounding the basic structure of a system that
protects the client from stressors. They are activated when stressors penetrate the normal
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line of defense (Neuman, 2011, p. 328). Clients with OUD may require bolstering of the
normal line of defense in order to be protected from stressors.
Normal Line of Defense
The normal line of defense is the model’s outer solid circle (see Figure 1), which
represents the adaptable health of a system that develops over time. Deviation from
wellness is measured (Neuman, 1995, 2011, p. 328) against this benchmark. In OUD
treatment, this is referred to as a client’s baseline.
Flexible Line of Defense
The model’s outer broken ring serves as a protective buffer for preventing
stressors from breaking through the normal line of defense. It is also known as the firstline protective mechanism (Neuman, 1995, 2011). The flexible line of defense is
bolstered through engagement in treatment and utilization of supports and resources in
the environment.
Health
The illness-to-wellness continuum is dynamic; optimal wellness is achieved when
the system’s needs are met. Wellness occurs when all system subparts are interacting in
concert with the whole system (Neuman, 1995, 2011). Ideally, health is restored when an
individual receives effective treatment and the disease process due to OUD is stabilized.
Illness
The opposite end of the continuum from wellness, which represents a state of
disequilibrium, instability, and energy depletion (Neuman, 1995, 2011). May occur when
OUD goes untreated and results in poor health.
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Stressors
Stimuli that have the potential to disrupt system balance; the outcome may be
positive or negative depending on interpersonal, intrapersonal, and extrapersonal forces
(such as coping ability, support systems, and treatment access;Neuman, 1982, 1995,
2011). Stressors exist in the client system and the environment, and may be a precipitant
to OUD.
Prevention as Intervention (Three Levels)
Primary prevention is anticipation of a stressor and accounting for its risk to the
health of a system. Secondary prevention is the utilization of interventions after
symptoms have already developed. The client’s internal and external resources are
mobilized in order to strengthen resistance. Tertiary prevention occurs after active
treatment, and focuses on adaptation and adjustment toward optimum wellness as well as
maintaining it (Neuman, 1982, 1995, 2011). All levels of prevention are utilized in OUD
treatment, from anticipating relapse, participating in treatment once symptoms have
developed, and stabilizing an individual and family who are experiencing advanced
stages of OUD.
Reconstitution
Reconstitution occurs after treatment for negative reactions to the stressor. It
represents the return of the system to stability prior to the stressor’s intrusion. Stability
may be at a higher or lower level than before the system experienced the stressor
(Neuman, 1982, 2011). The goal of treatment for OUD is to restore balance, promote
reconstitution, and stability, while minimizing the effects of future stressors.
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Figure 1: The Neuman Systems Model (Copyright 1970, The Neuman systems
model (5th ed., [page 13], Upper Saddle River, NJ: Pearson). Reproduced with the
permission of Betty Neuman and Jacqueline Fawcett.

Neuman Systems Model and Opioid Use Disorder
Few studies exist that examine the problem of substance abuse from the
perspective of the NSM. Several studies have been conducted that examine other health
problems such as diabetes and dementia using the theoretical framework of the NSM.
Research has been conducted on the education of persons with diabetes, reducing burden
on caregivers of persons with dementia, psychosocial support of vulnerable
schoolchildren, optimal aging, and pediatric gastroenteritis applying the NSM (Demir &
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Platin, 2017; Edelman & Lunney, 2000; Fawcett & Foust, 2017; Olowokere &
Okanlawon, 2015; Sher-Pin, 2017).
Two sources describe the development of interventions for substance abuse
problems utilizing the NSM as a theoretical framework. Although they are not research
studies, they discuss the generation of strategies to counter health risks due to substance
abuse problems. Mynatt and O'Brien (1993) describe a community-based peer-assisted
intervention program created to respond to the problem of chemical dependency among
nurses. They implemented approaches at the primary, secondary, and tertiary levels, by
forging community partnerships between a university, a school of nursing, local nursing
organizations, and healthcare providers to provide services for impaired nursing
professionals.
Rayan (2016) conducted a literature review on factors associated with smoking
among Jordanian adolescents, prior to developing an intervention program to prevent and
regulate smoking in this population. The results of the review determined the presence of
complex physiological, psychological, sociocultural, developmental, and spiritual factors
underlying adolescent smoking, which require prevention efforts at the primary,
secondary, and tertiary levels identified in the NSM.
Neuman Systems Model as a Theoretical Framework for Opioid Use Disorder
The NSM provides one theoretical framework for this study. In this research, the
open system of interest is the individual with OUD. In the model, individuals with OUD
are organisms that possess basic structures such as a genetic predisposition to OUD, as
well as response patterns unique to OUD. Further, they may possess physical strengths
and weaknesses, ego structures, and elements in common with other persons with OUD.
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Humans often experience stressors including trauma, pain, loss, deprivation, and cultural
change, which may modify responses to stressors. The normal defense lines may vary
from person to person depending on age and developmental stage, as well as
intrapersonal, extrapersonal, and interpersonal factors. An individual’s reaction to stress
depends on their basic structure, learned resistance, and natural resistance, and the
timing of encounter with the stressor. OUD may be viewed as a form of learned
resistance to stressors. The nurse or HCP, using a holistic approach, assists in bolstering
lines of resistance to stressors that reduce the risk of harm to an individual with OUD.
The nurse may provide interventions at the secondary or tertiary prevention levels when
the resistance lines are penetrated. The aim of interventions are to restore an individual to
health and balance. At the level of secondary prevention, the nurse assesses the severity
of OUD and treats the signs and symptoms that may be present. At the tertiary prevention
level, the nurse assists an individual with OUD to adapt to an existence without opioids,
anticipate the likelihood and risk of relapse in order to prevent it (strengthening lines of
defense), and assists the individual to return to a state of health and maintain it once they
no longer use opioids.
According to the NSM, the main focus of this study was to examine the impact of
adding tertiary prevention level variables (psychosocial treatments provided by nurses
and HCPs) such as individual, group, and family counseling, Narcotics Anonymousbased peer support, and other peer support, to secondary prevention level variables
(medication treatment with BUP/NX) on several outcome variables. These include
treatment utilization outcomes, medication utilization, opioid use, and substance use. The
NSM in OUD treatment is illustrated in Figure 2.
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Figure 2: Neuman Systems Model in opioid use disorder treatment.
Strengths and Weaknesses of the NSM
A main strength of the NSM is its utility across a broad range of specialty areas of
nursing including administration, education, and nursing practice. An open system is
viewed as an individual, family, or community. It emphasizes the three levels of
prevention and health promotion that are key principles in nursing practice. Neuman
provides easily understood definitions of key terms (Alligood, 2014). Weaknesses of the
model include the need for clarification of terms used, (e.g., distinction between
intrapersonal and extrapersonal). Further, the theory does not specify meanings of lines of
resistance and sources of energy referred to in the model and, questions have been raised
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as to how accurate the model is in representing human beings and their interactions in the
environment (Heyman & Wolfe, 2000).
Summary of Theoretical Framework
Identifying OUD as a chronic neurobiological disease that presents with periods
of relapse and remission, and has no cure implies biological treatment (medication) is
necessary that targets symptoms and assists patient with ongoing management perhaps,
over a lifetime (ASAM, 2011a). Furthermore, managing OUD requires patient-oriented
and individualized treatment that targets the brain itself, as well as the changes that have
occurred due to long-term opioid abuse.
The NSM draws on a number of concepts from general systems theory, Gestalt
Theory, and ideas from Neuman’s own clinical work; Neuman proposes that individuals
are open systems interacting with one another and the environment (Neuman, 1982). The
NSM is a dynamic, open, and systems approach to nursing care of the client with OUD.
The NSM suggests that certain individuals possess basic structures and unique response
patterns that predispose them to OUD. Interventions by the nurse and HCPS are aimed at
primary, secondary, and tertiary prevention levels in order to assist persons to achieve
reconstitution and stability through long-term management of the disorder.
The main focus of this research was to examine the impact of adding tertiary
prevention level variables (psychosocial treatments) such as individual, group, and family
counseling, and self-support approaches, to secondary prevention level variables
(medication treatment with BUP/NX) on several outcome variables. These include
treatment utilization outcomes, opioid use, and substance use.
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Key Definitions
Cocaine
A highly addictive stimulant drug made from the coca plant. It increases the levels
of dopamine in the center of the brain controlling pleasure. Taken in large quantities may
result in death (NIDA, 2016a).
Counseling and Psychosocial Treatments
Includes individual, group, or family counseling, peer-support, and self-help
models. Focused on halting opioid use, building coping skills, adherence to treatment and
recovery, and preventing relapse. Available in inpatient, outpatient, residential, and
primary care settings (SAMHSA, 2018a).
Medication Treatment
Medication treatment is the use of specific medications (BUP BUP/NX)
combined with counseling and psychosocial treatments. Assists in maintaining
abstinence, preventing relapse and opioid overdose (SAMHSA, 2018b).
Medical Management
Process in which healthcare professionals provide medication, brief counseling,
monitoring of drug use, medication adherence, and referrals to other services as necessary
to improve patient’s health (Kampman & Jarvis, 2015; SAMHSA, 2018a).
Opioids
Opioids are a class of drugs that include synthetic opioids, pain relievers available
by prescription such as oxycodone, hydrocodone, morphine, and codeine, and the illegal
drug heroin (NIDA, 2018b).
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Opioid Use Disorder
A pattern of opioid use leading to clinically significant impairment. Often
manifested by (a) opioids taken in larger amounts or longer than intended, (b) persistent
desire or unsuccessful efforts to control opioid use, (c) a great deal of time spent in
activities required to gain the opioid, use it, and recover from its effects, craving or strong
desire to use opioids, among others (APA, 2013).
Treatment Adherence
Taking prescribed medications and following treatment plan as directed by HCP
in order to meet treatment outcomes.
Visit Compliance
Attending scheduled appointments recommended by HCP on a consistent basis.
Review of Literature
Research has been conducted on the effectiveness of buprenorphine (BUP),
methadone, and naltrexone added to psychosocial treatments and medical management of
OUD. Studies have examined the effectiveness of psychosocial treatments such as
individual, group, and family counseling, cognitive behavioral therapy, contingency
management, and inpatient, outpatient, and residential treatment. Findings of studies
analyzing the addition of psychosocial treatments to BUP treatment suggest it does
benefit some individuals with OUD. Additional research is needed, however, to
determine the effectiveness of psychosocial treatment given that most providers of
medication treatment require patients to receive it. Further, there is a lack of research that
analyzes the impact of specific psychosocial treatment type on medication treatment with
BUP (Kampman & Jarvis, 2015, p. 39). Findings of studies that examine delivering

33

medical management along with BUP in primary care settings suggest it is highly
effective for assisting patients to meet treatment outcomes. What follows is an analysis of
selected studies that examine the effectiveness of psychosocial treatments, and medical
management in primary care settings when added to BUP treatment for OUD.
Buprenorphine and Buprenorphine/Naloxone
Due to the actions and properties of buprenorphine (BUP), it is highly effective
for treating OUD. It acts by lowering risk of abuse and physical dependence, possesses
fewer withdrawal symptoms, has a high-ceiling effect at increased doses, and has
improved safety over opioid full agonists. It is often combined with naloxone (NX) to
reduce the potential for abuse since NX acts by blocking opioid receptors, and therefore
blocking opiates (National Alliance of Advocates for Buprenorphine Treatment
[NAABT], 2016; NIDA, 2017). BUP and BUP/NX are widely used and have
significantly improved treatment outcomes for OUD.
Buprenorphine and Psychosocial Treatment
Several studies have evaluated the effectiveness psychosocial treatments added to
buprenorphine (BUP) or buprenorphine and naloxone (BUP/NX). Psychologically based
therapies are currently recommended for persons receiving medications for OUD despite
mixed results of research findings of their effectiveness (W. Ling et al., 2013; Otto et al.,
2014; Stein et al., 2015). A variety of approaches are presently used including individual,
family, or group counseling, cognitive-behavioral therapy, self-support groups, and
contingency management among others (Kampman & Jarvis, 2015; NIDA, 2018g).
The findings of several studies suggest that combining BUP or BUP/NX with
individual therapy, group counseling, family counseling, and contingency management is
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effective for some individuals versus standard treatments such as health education or
inpatient detoxification. For example, Berger, Pulido, Lacro, Groban, and Robinson,
(2014) conducted a retrospective review of 30 subjects receiving BUP, who were
assigned to one of two treatment conditions, individual counseling or group therapy.
Subjects in group therapy had significantly greater treatment retention than those in
individual therapy (Berger et al., 2014). In another example, Brigham et al. (2014)
randomly assigned 104 subjects receiving BUP to one of two treatments. The first, a
comprehensive psychosocial intervention called Community Reinforcement Approach
and Family Training for Treatment Retention (CRAFT-T), and the other, a standard form
of counseling. Participants receiving CRAFT-T were significantly more likely to remain
in treatment and abstain from opioids, suggesting that adding family therapy to BUP
benefits some individuals with OUD.
Kosten, Poling, and Oliveto (2003) conducted a randomized, double-blind trial of
75 subjects treated with BUP maintenance for 6 months. The subjects had been assigned
to one of four treatment conditions: desipramine plus contingency management (CM);
desipramine without CM; placebo plus CM; and placebo without CM. The escalation of
CM was eliminated at 3 months. At months 5 and 6, the response required to receive
vouchers increased to up to two and then three drug-free urine samples. The CM groups
showed a decline in opioid and drug-free urine samples. The desipramine plus CM
treatment arm had a significantly greater decline in drug-free urine samples than placebo.
Subjects on BUP, and desipramine plus CM were able to abstain from illicit opioids and
drugs, but not after the response requirement had been increased. This suggests that an
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additional intervention combined with CM may be necessary in order to assist patients
meet treatment goals.
Katz et al. (2011) randomly assigned 240 subjects receiving BUP at a publicly
funded 30-day detoxification clinic to three treatment conditions: IRI (an approach to
improve retention), IRI and case management, or standard treatment (ST). Subjects
receiving IRI, but not IRI and case management, were significantly more likely to
complete detox and remain in treatment longer, demonstrating the addition of counseling,
effectively assists some patients to attain OUD treatment goals.
The findings of two analyses of a long-term study suggests that BUP continues to
assist subjects to remain abstinent from opioids for many months after starting BUP
maintenance, and that psychological therapies have little added benefit to treatment with
agonists with the addition of weekly medical management [MMT]; (Potter et al., 2015;
Weiss et al., 2015). Potter et al. (2015) examined participants in the Prescription Opioid
Addiction Treatment Study (POATS), a multisite, randomized trial that analyzed
treatment outcomes of buprenorphine-naloxone treatment. A total of 252 subjects from
the study completed an 18-month follow-up telephone assessment. Overall, participants
were significantly more likely to remain abstinent from baseline to month 18. Further
analysis demonstrated no significant differences in outcomes with the addition of
psychosocial treatment to BUP and MMT (Potter et al., 2015). In another analysis of the
POATS, Weiss and Rao (2017) found that subjects who remained on BUP were
significantly more likely to abstain from opioids.
Research on the effectiveness of technological interventions for delivering
counseling as an adjunct to medication treatment suggest that psychological interventions
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administered via computer or Internet, may be not only effective but hold promise for
widening treatment access (Bickel, Marsch, Buchhalter, & Badger, 2008; Christensen et
al., 2014; Reutsch & Tkacz, 2010). Bickel et al. (2008) randomly assigned 113 subjects
receiving BUP to one of three treatment conditions: a therapist-delivered Community
Reinforcement Approach (CRA) with vouchers (a form of CM); computer-based CRA
with vouchers; or standard care. The therapist- and computer-delivered CRA groups
produced comparable weeks of continuous opioid-free and drug-free urine samples and,
significantly more weeks of abstinence than standard care. The comparable effectiveness
of the computer-delivered intervention has implications for widening available
treatments, an important strategy in combating the opioid epidemic.
In another example, (Christensen et al., 2014) randomly assigned 170 adults
receiving BUP maintenance to two treatment conditions: a community reinforcement
intervention (CRA) delivered by computer along with contingency management versus
contingency management alone. Subjects receiving CRA and contingency management
were significantly more likely to abstain from using illicit opioids and remain in
treatment. Finally, Ruetsch, Tkacz, McPherson, and Cacciola (2012) randomly assigned
1426 participants to receive either BUP in combination with a telephone-based program
called Here to Help (HTH), or BUP alone. Subjects in the HTH groups were significantly
more likely to abstain from using illicit opioids. In summary, although psychosocial
treatments added to BUP demonstrate mixed results, research suggests they are effective
for some individuals whether delivered technologically or in person.
While the findings of several studies suggest psychologically based therapies
extend benefits of BUP treatment, other studies demonstrate either mixed results or little
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benefit to subjects. For instance, Mitchell et al. (2013) randomly assigned 300 AfricanAmerican subjects on BUP maintenance at one of two community-based clinics, to either
outpatient counseling (OP; 3.6 hours per treatment week) versus intensive outpatient
counseling (IOP; 5.3 hours per treatment week). No significant differences were noted
between treatment arms in abstaining from using illicit opioids or other drugs. This
suggests that increasing the intensity of OP may not necessarily increase the effectiveness
of medication treatment with BUP.
In another example, Stein et al. (2015) randomly assigned 49 adults on BUP/NX
maintenance to receive either a 50-minute Distress Tolerance (DT) therapy session or
standard health education (HE) over a 4-week period. The DT therapy produced a small
but nonstatistically significant difference in illicit opioid use, suggesting psychosocial
treatments have little added benefit to medication treatment.
Buprenorphine and Medical Management
Although research findings are mixed on the effectiveness of adding psychosocial
treatments to BUP treatment, the results of studies examining delivery of BUP via MMT
in primary care settings, suggest it is effective (Accurso & Rastegar, 2016; Fiellin et al.,
2014; Liebschutz et al., 2014; W. Ling et al., 2013; Lucas et al., 2010; Mintzer et al.,
2007; Weiss et al., 2015). In the model referred to as MMT, medication and treatmentfocused counseling are provided by a primary care physician, nurse practitioner, or other
HCP in an office-based primary care setting (ASAM, 2015; Kampman & Jarvis, 2015;
SAMHSA, 2018c).
In fact, a study by W. Ling et al. (2013), underscores the effectiveness of MMT
versus psychosocial treatments added to BUP treatment. The researchers randomly
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assigned 202 subjects stabilized on BUP for a period of 2 weeks, to four treatment
conditions in an outpatient clinical research center for 16 weeks. Participants either
received MMT, cognitive behavioral therapy (CBT), contingency management (CM),
CBT and CM, or no behavioral treatment. There were no significant differences between
groups in remaining abstinent from opioids. The researchers found no clear evidence that
CBT or CM reduces illicit opioid use, despite that at the time of the study, the Controlled
Substances Act required prescribers to refer patients on BUP to counseling (W. Ling et
al., 2013).
The findings of a study by Accurso and Rastegar (2016) further support the
benefit of MMT combined with BUP treatment in greater than 16mg/day dosages. The
researchers conducted a retrospective review of 297 patients receiving BUP in primary
care for 3 or more months. Comparison groups were generated based on the dosage of
BUP (16mg/day or lower, and 16mg/day or greater) they received. Subjects receiving
doses greater than 16mg/day were significantly more likely to abstain from illicit opioids
and remain in treatment than subjects receiving 16mg/day or less. The researchers
suggest BUP delivered in higher doses is highly effective, and that lower doses may
actually be harmful (Accurso & Rastegar, 2016).
Fiellin et al. (2014) conducted a randomized trial among prescription opioid
dependent subjects (n = 113) and examined the effectiveness of BUP/NX taper versus
BUP/NX maintenance therapy delivered via MMT. Subjects on BUP/NX maintenance
versus tapered doses were significantly more likely to submit opioid- and drug-free urine
samples over the course of treatment. The findings suggest BUP maintenance is more
effective in assisting patients to remain abstinent from opioids versus tapering dosages.
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In a cohort study, Mintzer et al. (2007) examined 99 subjects from two primary care
settings enrolled in BUP/NX treatment for OUD. At 6 months, 54% of subjects remained
abstinent from opioids (determined by urine drug screens). There was no significant
correlation between abstinence and site of care, drug of choice, level of income, or
dosage of BUP/NX. Again, the results suggest delivering BUP/NX treatment in primary
care is highly effective.
Moreover, the findings of a study by Cunningham et al. (2013) suggest that MMT
combined with BUP treatment is effective in some patients for achieving abstinence from
opioids and cocaine. The researchers analyzed the effectiveness of BUP delivered via
MMT among opioid-dependent cocaine users versus non-users over 6 months. The
results revealed no significant differences in treatment retention, or self-reported opioid
use between cocaine users and non-users. The results underscore that opioid-dependent
cocaine users benefit from office-based BUP treatment and should be included in these
treatment programs (Cunningham et al., 2013).
The results of research conducted by Parran et al. (2010) suggest that BUP added
to MMT not only targets opioid abstinence, but increases engagement in self-support
groups, increases rates of employment and overall functioning. The researchers
conducted a retrospective review of 110 opioid-dependent subjects who received IOP
combined with BUP/NX for 5 weeks, followed by 12 weeks of weekly aftercare. After
IOP, all subjects remained on BUP/NX and were referred to primary care physicians for
MMT in an office-based setting. At an 18-month follow-up assessment, the researchers
found subjects who remained on BUP/NX were significantly more likely to abstain from
using illicit opioids, engage with 12-step recovery, be employed and demonstrate
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improved functioning. The results suggest that BUP/NX coupled with long-term MMT is
effective not only for achieving primary treatment outcomes, but also improved quality of
life (Parran et al., 2010).
Additionally, the findings of two studies highlight the benefits of MMT combined
with BUP treatment among opioid-dependent patients in targeting successful treatment of
chronic diseases. Lucas et al. (2010) compared outcomes of BUP/NX treatment among
93 HIV-infected, opioid-dependent subjects, delivered either in a clinic-based setting
versus an opioid treatment program. Subjects receiving treatment in the clinic-based
setting attended significantly more HIV primary care visits and were significantly less
likely to submit positive UDS for opioids and cocaine. Liebschutz et al. (2014) compared
a “linkage” intervention (BUP/NX maintenance and successful transition to office-based
treatment) versus simple detoxification (and taper) among 139 opioid-dependent subjects
who had been hospitalized for medical illnesses and had no prior treatment for OUD.
Subjects in the linkage group were significantly more likely to abstain from illicit opioids
(self-report) and remain in treatment at 6 months. This study underscores the potential of
actively targeting opioid-dependent medically ill persons for BUP/NX treatment in
medical settings and primary care (Liebschutz et al., 2014).
Summary of Review of Literature
This review examined current research on buprenorphine (BUP) treatment for
OUD. Studies in the review analyzed the effectiveness of adding psychosocial treatments
and medical management to medication treatment in primary care and addiction
treatment settings. The findings suggest that medical management combined with
medication treatment with BUP is highly effective for targeting abstinence from illicit
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opioids and treatment retention. The results of studies analyzing the effectiveness of
adding psychosocial treatment to medication treatment are mixed. Additionally, BUP
treatment administered in primary care settings is effective for targeting illicit use of
opioids and cocaine among opioid-dependent cocaine users. Further, medication
treatment improves engagement in medical treatment for co-occurring chronic diseases
such as HIV.
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CHAPTER 3
METHODOLOGY
This chapter describes the purpose of the study, the research design, the use of the
electronic health record (EHR), the study sample, setting, and limitations. Additionally,
the constructs, methods of measurement, study procedures, data analysis, and power
analysis are outlined. Finally, the protection of human subjects and study limitations are
discussed.
Purpose of the Study
The focus of this research was to examine the relationship between individual
counseling status and opioid use treatment outcome variables in patients receiving
medication treatment for OUD. The outcome variables examined included treatment
utilization, medication utilization, opioid and substance use, and treatment retention. This
relationship was examined while controlling for important confounding variables (e.g.,
gender, age, race, ethnicity, PTSD/trauma, CJS involvement, and anxiety).
Research Design
A nonexperimental correlational design that utilized secondary analyses of EHRs
was used in this study. In nonexperimental correlational research, the independent and
dependent variables are not manipulated by the researcher (Tabachnick & Fidell, 2014, p.
2). While it is difficult to attribute causality to an independent variable (or predictor
variable) in correlational designs, it is useful for describing the direction and significance
of a relationship between an independent and dependent variable (Polit, 2014, p. 68).
Additionally, a correlational research design enables researchers to make predictions
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between variables (Polit, 2014, p. 216). The use of secondary data permitted the
researcher to use extant data sources in the EHR.
Secondary Data Analyses of EHRs
Secondary analyses of routinely collected data such as EHRs offers an
opportunity to gain knowledge that may improve patient outcomes (MIT Critical Data,
2016). While collecting primary data is one of the best ways to answer research
questions, it is not always logistically or economically feasible (Vartanian, 2011).
“Secondary data can include any data that are examined to answer a research question
other than the question(s) for which the data were initially collected,” (Vartanian, 2011,
p. 3). The EHR produces and accumulates immense amounts of data, which provide
opportunities to test hypotheses answer research questions and further advance
healthcare. Sources of data may include outpatient and inpatient clinical notes, diagnostic
and laboratory tests, and computerized databases among others. Some of the advantages
and challenges of conducting secondary data analyses are described:
Advantages of Secondary Data Analyses of EHRs
One of the main benefits of secondary analyses is that data collection has already
taken place and the research study completed, saving considerable time and monetary
resources. Secondly, data may be of higher quality in EHRs since accurate documentation
of patient data is deemed important in caring for patients. Some data sets have
considerable breadth, permitting the selection of a sample that may be more
representative of a target population. Large data sets also permit testing of a large number
of variables (Koziol & Arthur, 2011). Additionally, with large data sets such as EHRs,
researchers may take advantage of advanced statistical techniques, (e.g., fixed-effect
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modeling and hierarchical linear modeling). Large data sets often span years or months,
permitting subjects to be studied over long periods. Researchers are able to capture
intergenerational effects and long-terms effects of specific events and healthcare
interventions (Vartanian, 2011).
Disadvantages of Secondary Data Analyses of EHRs
There are a number of pitfalls to conducting secondary data analyses on EHRs.
The first challenge is there has been no control of what data was actually collected, and
whether it will answer the research question being asked (Vartanian, 2011). In addition,
there is little chance of contacting participants for additional data or follow-up
information. Secondary data analysis may threaten the research process by encouraging
researchers to consider only questions that can be answered by the available data
(Vartanian, 2011). It is also important for the researcher to keep in mind, as with any data
set, regardless of size, errors may have occurred during the data collection process that
can negatively impact the reliability and validity of the data collected (Smith, 2008).
Solutions to Pitfalls of Secondary Analyses of EHRs
To offset problems with conducting secondary analyses, several strategies are
recommended (Koziol & Arthur, 2011; MIT Critical Data, 2016; Smith, 2008; Vartanian,
2011). These include the following: (a) Recognizing the fallibility of EHRs; that is, they
are rarely fully complete or correct. (b) Understand bias and missing data; for example,
selection bias may occur if subjects in the sample have sought medical care within a
system that uses an EHR. Confounding bias is a risk in that it is difficult to account for
confounding variables that influence the independent and dependent variables. Missing
data poses a risk in that examining only complete records threatens the generalizability of
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the results. (c) Ensure protection of patient privacy by de-identifying and safely storing
all data. Additional suggestions for maintaining rigor of study procedures include the
following: address sampling concerns a priori; operationalize variables; ensure
consistency among data abstractors; develop a data abstraction procedure manual and
procedure forms; develop well-articulated inclusion and exclusion criteria; consider intrarater and interrater reliability; conduct a pilot study, and attend to ethical considerations
(Vasser & Holzmann, 2013).
Setting and Sample
All patient data was provided by a national office-based outpatient addiction
treatment center that primarily provides medication treatment to patients with OUD. In
order to receive treatment at a center, patients had to meet criteria for an opioid abuse
disorder according to the Diagnostic and Statistical Manual of Mental Disorders (5th ed;
APA, 2013). At each center, a biopsychosocial assessment and treatment plan was
created for each patient. Treatment planning included individualized patient-centered care
provided by physicians and nurse practitioners. The national treatment facility utilized an
EHR that allowed for robust monitoring of contingency planning and management. All
offices and all clinicians had access to this centralized EHR.
OUDs are treated primarily with buprenorphine in a group-practice setting.
Although most of the patients in the sample had an OUD, the treatment centers offered
evidence-based treatment for a range of substance use disorders including alcohol, opioid
and polysubstance use disorders among others (Bloomberg, 2016). Given the focus of the
study, only patients who received treatment for OUD were included in analyses. Given
changes in treatment protocols regarding mandated counseling, patients who received
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treatment between January 2016 and January 2018 were included in the study. Although
99% of the patients treated at this national facility were over the age of 18, patients under
the age of 18 were removed from the data file prior to analyses.
In addition to changes in treatment protocols over the past decade at the treatment
facility, there were some differences in treatment protocol by state. For example, until
very recently, there was no care coordination at Massachusetts sites due to state
legislation, but in Pennsylvania, all sites had patient care coordination. Care coordination
refers to collaborating with patients, HCPs, within the company and community agencies
to maintain accurate information, make referrals, schedule appointments, and facilitate
alternative or higher level care recommended by the treatment team. Since the majority of
the sites were in Massachusetts, and care coordination had begun after January 2018,
only patients who were seen by providers in Massachusetts were included in the analyses
to reduce the confounding of care coordination.
Thus, in summary, inclusion criteria included patients treated at a national
outpatient treatment facility who received OUD care in the state of Massachusetts
between January 2016 and January 2018. Exclusion criteria included patients who
received care at a treatment facility in Massachusetts due to a non-OUD primary
substance use disorder and patients who were under the age of 18.
Sample Size
An important aspect of conducting a research study is determining the sample
size. Ideally, the sample represents the population from which it is drawn so that findings
can then be generalized to the target population (Kadam & Bhalerao, 2010). The sample
size depends on several elements: the acceptable level of confidence, power of the study,
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expected effect size, underlying rate of the condition under study in the population, and
standard deviation in a population (Kirby, Gebski, & Keech, 2002).
Power Analysis
Using G*Power 3.1.9.2, a power analysis to identify the required sample size was
performed. To estimate the necessary sample size the following parameters were used: a
small effect size (f = 0.1), α = 0.05, 2 groups, and 5 covariates. The identified necessary
sample size was 787. Based on information provided by the national treatment center,
and verified by Dr. Chiodo, from January 2016 through January 2018, there is data in the
EHR for 16,013 Massachusetts patients. Among these 16,013 patients, 13.221 were
treated for OUD. Thus, there was ample statistical power to identify even a very small
effect.
Operational Definition of Variables
The EHR contained all the information that was used in this study. The data had
been provided to Dr. Chiodo in comma-separated values (CSV) format prior to the study.
All CSV tables were converted to SPSS files and were merged by patient medical record
number (MRN). All MRN and other identifying information were removed prior to data
transfer and analysis. A description of all study variables is provided below:
Independent Variables
The main independent variable examined in this study was individual counseling.
The reliability of self-reported individual counseling data was evaluated by the presence
of scans confirming attendance at counseling visits. Based on center policy, all patients
were required to bring in evidence of counseling activity. The evidence was scanned into
the EHR. Presence of counseling confirmation was evaluated in 780 random patients.
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Among the 780 patients randomly chosen, 111 patients did not meet inclusion
criteria (e.g., did not live in MA, not a Suboxone patient, did not have lab visit data).
Confirmation of counseling for the remaining 669 eligible patients was examined. A
confirmed counseling scan that was present within 1 year of the last treatment date was
identified as confirmation of current counseling. Scans confirming counseling but were
older than 1 year from the date of the last treatment visit were identified as evidence of
prior counseling while in treatment. Among the 669 patients, only 27.1% of the patients
had scans present in the EHR confirming ever having attended counseling during
treatment. Only 17.5% of the patients had scans present in the EHR confirming they
attended counseling while in treatment. Counseling was a categorical (nominal) variable.
Dependent Variables
Several dependent variables were examined in this study including treatment
utilization, medication utilization, opioid use, total time in care, time since last visit, and
treatment retention. Although not a part of the study aims, other types of substance use
were examined. Each variable is discussed below:
Treatment Utilization
Each time a patient was scheduled for a visit, an encounter is documented in the
EHR. There are several types of visits where an encounter is created: a maintenance visit,
a random maintenance visit, a rejoin visit, a rescheduled visit, an induction visit, a
random urine screen visit, and other encounters (e.g., phone conversation to schedule an
appointment). If a patient did not show for an appointment, the appointment was
identified as a “no-show” visit. Tracking the frequency of these visits and the frequency
of visit utilization and compliance was used to measure treatment utilization. Patients that
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are more compliant with treatment plan are considered to be progressing in treatment by
facility treatment providers (Y.-I. Hser et al., 2016; Kampman & Jarvis, 2015, p. 11;
Timko et al., 2016).
In some instances, patients who returned to the facility after having discontinued
treatment required an additional visit in order to be inducted on buprenorphine and
naloxone, also known as Suboxone. Returning patients, depending on the length of time,
would often be required to “rejoin” the program, which might also require another
“initial” visit and induction visit. The number of times there was more than one induction
visit and the number of times there was more than one initial visit, along with the total
number of “rejoin” visits, was totaled and identified as the total number of times a patient
had not been seen by a provider within 30 days was summed and was referred to as the
number of care interruptions.
Two additional treatment utilization variables were total time in care and the time
since the last visit. Total time in care was calculated based on the number of years a
patient was in treatment. The amount of time due to care interruptions was removed from
the total time. Time since last visit was defined as the period of years since the last
treatment visit.
Medication Utilization
Medication utilization is defined as taking medication (e.g., buprenorphine) as
prescribed by the HCP according to the substance use treatment plan at the treatment
center. Urine screen data was available for every visit for each patient in the EHR. OUD
medication use was examined in this urine screen panel. Patients whose urine screens
show evidence of medication utilization were coded as utilization of their medication for
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that visit (positive). Patients whose medication values were below standard cutoff values
were identified as lack of medication utilization for that visit (negative). The total number
of positive screens divided by the total number of screens performed (i.e., percent
positive) was used in analyses.
Opioid Use
When patients’ urine samples were screened as indicated above, the presence of
opioids was also investigated. Some of the opioids examined were heroin, morphine,
hydrocodone, hydromorphone, oxycodone, and fentanyl. In addition, a general opiate
screen was performed. Patients whose urine screens show evidence of any opioid were
coded as positive for that visit. Patients whose medication values were below standard
cutoff values were identified as negative for opioids. The total number of positive screens
divided by the total number of screens performed (i.e., percent positive) was used in
analyses.
Retention
The final treatment utilization variable examined was retention. A patient was
considered in treatment if they were still receiving care at the end of the study period.
Covariates
In addition to the variables already presented, several covariates were available in
the EHR. Covariates included gender, age, race, ethnicity, history of PTSD/trauma
(yes/no), history of anxiety (yes/no), and history of involvement in the CJS (yes/no).
During intake at the treatment facility, a patient’s gender, age, race, and ethnicity are
recorded in the EHR. In the case of gender, it is documented as either male or female.
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Since the sample was primarily White, a White/non-White variable was constructed and
used in analyses.
PTSD/Trauma
During intake, HCPs collect data on medical and social history. Data regarding
post-traumatic stress symptoms may be entered in the EHR in free text format in several
locations. After translating all text data to lowercase, syntax was written in order to
identify patients with a diagnosis of PTSD. The following phrases were identified in the
text fields and flagged as positive for PTSD: ptsd and post-traumatic stress. In addition, a
patient with any PTSD diagnosis code was identified as positive for PTSD. Like PTSD,
data regarding a history of trauma could be entered into the EHR in several locations. All
of these fields were in free text format. Text from 500 patients was examined in order to
identify specific phrases used to identify trauma in the EHR. After translating all text to
lowercase, syntax was written to identify cases with trauma.
The presence of trauma was also identified using text data. The following phrases
were used: stabbed, gunshot, traumatic, abused, hostage, victim of, rape, traumatic
abuse, childhood abuse, hx of abuse, intimate partner violence, domestic violence, gun
shot, bullet wound, trauma hx, physical abuse, sexual abuse, emotional abuse, assaulted,
abuse as child, stab wounds, beat up, being shot, verbal abuse, bullet lodged, shrapnel,
stab injury, sexually abused, physically abused, mugging, traumatic experiences,
emotionally abused, domestic violence, past sexual trauma, violent incident, abusive
relationship, stabbing victim, molested, and kidnapped. The presence of any of these
phrases was identified as positive for trauma. In this study, a variable was constructed
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that indicated patients had either a history of PTSD or trauma. If one or both were present
in the history, they were coded either yes or no for PTSD/trauma.
Anxiety
HCPs at the treatment facility also collect medical history regarding anxiety.
There are several locations in the EHR where data related to a history of anxiety could
have been entered by a provider. In addition to a diagnosis code, text fields were used to
identify patients with a history of anxiety. After translating all text data to lowercase,
syntax was written to identify cases with evidence of a history of anxiety.
Criminal Justice System Involvement
HCPs at the treatment facility evaluate patients’ involvement in the CJS (i.e.,
probation, awaiting trial, and past incarceration) each quarter when the treatment plan is
evaluated. This data is identified via checkboxes. Providers are able to check whether
there are “pending criminal charges” or “resolved criminal charges.” If a patient is
positive for either, they are identified as involved with the CJS. In addition, several
patients were identified as having CJS involvement through a separate database for
patients who were subjects in a study being performed according to treatment center
location. All patients in the “Jail Database” were identified as positive for CJS
involvement.
The final covariate used when examining several of the treatment utilization
variables is total time in care. A patient who has been in treatment longer will by
treatment protocol have more patient visits and more opportunities for “no show” visits.
Thus, total time in care will be included as a covariate in all analyses examining
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treatment utilization variables with the exception of analyses examining total time in care
and time since the last visit.
Measurement of Variables
All variables were obtained from the EHR. The independent variable, individual
counseling (yes/no) is nominal in scale. All dependent variables are as ratio in scale with
the exception of treatment retention, which is nominal.
Procedures
As mentioned previously, all data was provided to Dr. Chiodo in individual CSV
data tables. Dr. Chiodo imported all data tables into SPSS and created a merged date file.
Files were merged based on patient MRN number. Before providing the data for analysis,
Dr. Chiodo removed all identifying patient information. IRB approval from the
University of Massachusetts Amherst was received prior to data transfer. Once the data
file was received, analyses were performed to evaluate study aims.
Data Analysis
Prior to beginning study analyses, all variable distributions were evaluated for
normality or data entry errors. All necessary transformations were performed prior to
analyses. Once distribution evaluation was completed, descriptive statistics were
calculated for all variables. Analyses by study aim are described below. The purpose of
Aims 1 and 2 was to better understand the relationships among the variables prior to
examining the impact of counseling.
Aim 1
What is the relationship between treatment utilization, medication utilization, and
opioid use in a sample of individuals with OUD receiving medication treatment?
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To examine the relationship between most treatment utilization variables and
medication utilization and opioid use, partial correlations were performed. All covariates
were included in the analyses.
Aim 2
Determine if medication utilization mediates the relationship between treatment
utilization and opioid use in patients receiving medication treatment.
For Aim 2, individual regression analyses were performed using the following
independent variables: maintenance visits, random maintenance visits, rescheduled visits,
other encounters, care interruptions, “no show” visits, retention, total time in care, and
time since last visit. All covariates were entered in the first step using simultaneous entry,
and the independent variable was entered in the second step of the regression model. In
the third step, medication utilization was added to the regression model. For all of these
analyses, the dependent variable was the percentage of positive opioid urine screens. To
evaluate the presence of mediation, the change in Beta for each of the independent
variables was examined. If there was a change in the value of the Beta from a significant
predictor to a nonsignificant predictor, medication utilization was considered a full
mediating factor.
Aim 3
Examine the impact of current and prior counseling on treatment utilization,
medication utilization, substance use, and treatment retention.
To examine study Aim 3, a similar regression strategy was employed. All
covariates were in step 1. If any of the covariates were nominal, dummy coding was
performed prior to including them in the analyses. The predictor was entered in the
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second step. The predictor variable was individual counseling. Regression analysis was
performed for the following dependent variables: maintenance visits, random
maintenance visits, rescheduled visits, other encounters, care interruptions, no-show
visits, total time in care, total time since the last visit, medication utilization, opioid use,
and treatment retention. Since treatment retention is nominal in scale, logistic regression
was employed.
Aim 4
To examine the comparative effectiveness of type of psychosocial treatment on
medication utilization, treatment utilization, and opioid use in patients receiving
medication treatment.
As will be described in Chapter 4, analyses to examine Aim 4 were not
performed.
Protection of Human Subjects
The secondary data set that was used for this research was information from an
EHR from an opioid abuse treatment facility in Massachusetts between January 2016 and
January 2018. The data was provided to Dr. Chiodo in CSV format. All CSV tables were
converted to SPSS files and merged by patient MRN. All MRNs and other identifying
information were removed prior to data transfer and analysis. There was minimal-to-no
risk to subjects as the data had already been collected and analyses were performed on
de-identified data. There was a slight risk to subjects due to loss of confidentiality. This
research was approved by the University of Massachusetts Amherst Internal Review
Board.
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Study Limitations
There were several limitations to this research. First, given the data was derived
from secondary data, there was a lack of control over data collected (Vartanian, 2011).
Secondly, errors may have occurred in the data collection process and recording of
information, which affected the reliability and validity of the data (Smith, 2008) and,
therefore, the generalizability of findings. In addition, many participants who received
treatment at the center, either had insurance or monetary resources to be treated for OUD,
limiting the generalizability of the findings to other populations with OUD. Other
limitations included necessities for participating in treatment such as transportation, the
treatment facility dispensed two types of medication treatment, and subjects were from a
nonrandomized sample. Finally, HCPs collected the data, thereby increasing the risk of
interviewer bias having affected the validity of data collected.
Strengths of the intended research included a large sample size and access to a
data set with considerable breadth, which permits examination of a large number of
variables. In addition, data had been collected over a long period, which permitted the
analyses of the long-term impact of treatments under study.
Summary
The focus of this research study was to examine the relationship between
individual counseling (current and prior) and opioid use treatment outcome variables in
patients receiving medication treatment for OUD. The outcome variables examined
included treatment utilization, medication utilization, opioid use, and treatment retention.
A nonexperimental correlational design using secondary analysis of EHRs was
used. All patient data was provided by a national office-based outpatient addiction

57

treatment center that primarily provides medication treatment to adults 18 years and older
with OUD. The findings of this research are expected to further advance and improve
treatments for OUD.
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CHAPTER 4
RESULTS
This chapter outlines the results of the study including sample characteristics,
distribution evaluation, bivariate, and multivariate analyses. Multivariate analyses are
presented for each study aim.
Sample Characteristics
The study sample consisted of 11,551 patients ranging in age from 19–84 years
(mean = 38.7, SD = 10.6). After outliers for age were winsorized, the range of ages was
19–68 years (mean = 38.7, SD = 10.5). The majority of the sample was male (58.2%),
White (95.6%), and non-Hispanic (85.1%). Although a small number of patients resided
in other states (1.8%), all received treatment within the state of Massachusetts. All
patients included in this sample received buprenorphine and naloxone (Suboxone) for
treatment of OUD.
Just over one quarter of the sample (28.2%) had either a PTSD diagnosis or
reported trauma in the EHR. There was further evidence of psychiatric comorbidity as
42.5% reported symptoms of anxiety. Just over 29% of patients (29.6%) acknowledged
they had been involved with the CJS.

Table 1: Characteristics of sample.
Variable
%
Sex (% male)
58.2
Race (% White)
95.6
Ethnicity (% Non-Hispanic) 85.1
PTSD (% yes)
13.1
Trauma (% yes)
15.1
Anxiety (% yes)
42.5
CJS involvement (% yes)
29.6
Note. CJS = criminal justice system.
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Counseling Experience
According to patient report, 35.9% of patients received individual counseling.
Additional types of reported counseling included group counseling (0.4%), Narcotics
Anonymous (N/A; 4.5%), peer support (such as SMART recovery; 0.6%), and IOP
(0.7%). Since so few patients received psychosocial treatment other than individual
counseling, only individual counseling was examined as an independent variable.
Table 2: Counseling patient report.
Type

%

Individual
35.9
Group
0.4
NA
4.5
Peer
0.6
IOP
0.7
Note. IOP = intensive outpatient treatment.

As previously mentioned, the reliability of self-reported individual counseling
data was evaluated by the presence of counseling confirmation. All patients, based on
center policy, were required to bring in evidence of counseling activity. The evidence
was scanned into the EHR. Confirmation of counseling attendance was examined for 669
patients. Among the 669 patients, 27.1% had evidence of having attended counseling at
one point in treatment. Only 17.5% of them had provided evidence of current counseling.
Treatment Utilization and Substance Use
Several variables were used to evaluate treatment utilization. These included the
following: random maintenance visits (mean = 0.9, SD = 1.6); maintenance visits (mean
= 40.8, SD = 43.3); “no-show” visits (mean = 4.6, SD = 5.3); rescheduled visits (mean =
4.8, SD = 7.00); number of other encounters (mean = 34.6, SD = 31.4); care interruptions
(mean = 1.1, SD = 1.4); total time in care (mean = 1.5, SD = 1.6), and time since last visit
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(mean = .6, SD = .7). Among patients in the sample, 43.2% had remained in treatment
and were considered “retained.”
All distributions were evaluated for normality and outliers. Outliers for care
interruptions were winsorized, while the following variables were log transformed due to
non-normal distributions: random maintenance visits, maintenance visits, “no show”
visits, rescheduled visits, and other encounters. Transformed variables were used in all
analyses.
Table 3: Treatment utilization descriptive statistics.
Variables
# random maintenance visits
# maintenance visits
# “no show” visits
# rescheduled visits
# other encounters
# care interruptions
# total time in care years
# time since last visit

Mean

SD

Min

Max

0.9
40.8
4.6
4.8
34.6
1.1
1.5
0.6

1.6
43.3
5.3
7.0
31.4
1.4
1.6
0.7

0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0

16.0
328.0
62.0
76.0
263.0
13.0
7.4
2.1

Medication utilization and substance use were determined by urine drug screen
results. Drug screens tested for the presence of Suboxone (mean = 83.5%, SD = 25.8%),
benzodiazepines (mean = 9.5%, SD = 17.1%), alcohol (mean = 15.3%, SD = 25.1%),
cannabis (mean = 36.7%, SD = 41.1%), amphetamines (mean = 5.2%, SD = 15.1%),
cocaine (mean = 17.6%, SD = 28.3%), and opioids (mean = 15.1%, SD = 18.6%).
Initially, medication utilization and substance use variables were not normally
distributed. Analyses were performed using log-transformed variables.
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Table 4: Medication utilization and substance use.
Substance (% positive)
Suboxone
Benzodiazepine
Alcohol
Cannabis
Amphetamine
Cocaine
Opioids

N
11326
11320
11307
11315
11317
11320
11326

Mean

SD

83.5
9.5
15.3
36.7
5.2
17.6
15.1

Min

Max

0.0
0.0
0.0
0.0
0.0
0.0
0.0

100.0
100.0
100.0
100.0
100.0
100.0
100.0

25.8
17.1
25.1
41.1
15.1
28.3
18.6

Relationship Between Gender and Demographic Characteristics
The relationship between gender, race, ethnicity, PTSD/trauma, anxiety, and CJS
involvement was evaluated via chi-square analysis (Table 5). The relationship between
these demographic variables and age was evaluated via independent t-tests (Table 6). Due
to high statistical power, a conservative alpha was used to evaluate statistical significance
(α = 0.01) in a bivariate analyses.
Females were more likely to identify as non-Hispanic (χ2 = 160.8, p<0.001),
report having experienced PTSD/trauma (χ2 = 251.9, p = p<0.001), and anxiety (χ2 =
149.4, p<0.001). Males, on the other hand, were more likely to have had CJS
involvement (χ2 = 17.4, p<0.001). There was no significant relationship between gender
and the likelihood of identifying as White (χ2 = 3.7, p = 0.056; see Table 5). Using a more
conservative value for alpha, there was not a significant relationship between age and
gender (t = 4.6, p = .038).
Table 5: Relationship between gender and demographic characteristics.
Males

Gender
Females

χ2

p

Demographic
Race (%White)
Ethnicity (% Non -Hispanic)
PTSD/Trauma (% Yes)
Anxiety (% Yes)
CJS Involvement (% Yes)

95.2
81.1
19.1
37.8
31.1

96.1
90.6
31.9
49.2
27.5

62

3.7
160.8
251.9
149.4
17.4

0.056
<0.001
<0.001
<0.001
<0.001

Relationship Between Gender and Counseling Experience
The relationship between gender and counseling was evaluated by chi-square
analysis (see Table 6.) With respect to patient-reported individual counseling experience,
women were significantly more likely to report having attended than males (χ2 = 120.0,
p<0.001). Males were more likely to have attended Narcotics/Alcohol Anonymous (NA)
(χ2 = 31.6, p<0.001). There were no significant between-group differences in counseling
confirmation scans indicating whether patients had ever been (χ2 = 0.3, p = .600), or
currently were in counseling (χ2 = 0.4, p = .547). Further, there were no significant
differences in attendance at group counseling (χ2 = 0.8, p = .383), peer support (χ2 = 0.0, p
= .908), and IOP (χ2 = 0.9, p = .337). Due to the low frequency of counseling experiences
reported for group counseling, NA, peer support, and IOP, only individual counseling
was analyzed.
Table 6: Relationship between gender and counseling.
Gender
Males
Females

χ2

p

Counseling Patient Report
Individuals Counseling (% Yes)
Counseling Ever Scan (% Yes)
Counseling Current Scan (% Yes)
Group (% Yes)
NA (% Yes)
Peer Support (% Yes)
IOP (% Yes)
Note. IOP = intensive outpatient treatment.

31.8
26.3
16.7
0.4
5.5
0.6
0.8

41.7
28.1
18.5
0.3
3.3
0.6
0.6

120.0
0.3
0.4
0.8
31.6
0.0
0.9

<0.001
0.600
0.547
0.383
<0.001
0.908
0.337

Relationship Between Gender and Treatment Utilization
The relationship between gender and treatment utilization variables was analyzed
via independent group t-tests (see Table 7). There was a significant relationship between
gender and attendance at random maintenance visits (t = -6.9, p<0.001), “other”
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encounters (t = -13.2, p<0.001), and total time in care years (t = -7.3, p<0.001) with
females reporting higher rates of attendance at all three. Females, however, demonstrated
higher rates of “no shows” (t = -8.0, p<0.001), and tendency to reschedule visits (t = 15.7, p<0.001), while males were more likely to experience care interruptions (t = 3.4,
p<0.01), and time since last visit (t = 3.9, p<0.001). There was no significant relationship
between gender and attendance at maintenance visits (t = -6.2, p = .655).
Table 7: Relationship between gender and treatment utilization.
Mean

SD

t

p

# random maintenance visits
Male
Female
# maintenance visits
Male
Female
# “no show” visits
Male
Female
# rescheduled visits
Male
Female
# other encounters
Male
Female
# care interruptions
Male
Female
# total time in care years
Male
Female
# time since last visit
Male
Female

0.4
0.5

0.6
0.6

-6.9

<0.001

2.9
3.1

1.5
1.5

-6.2

0.655

1.3
1.4

0.8
0.9

-8.0

<0.001

1.1
1.4

1.0
1.1

-15.7

<0.001

3.1
3.3

0.9
0.9

-13.2

<0.001

1.1
1.0

1.3
1.3

3.4

<0.01

1.4
1.7

1.6
1.7

-7.3

<0.001

1.2
1.1

0.7
0.7

3.9

<0.001

Note. Log-transformed variables were not used to allow for interpretation of the values.
Winsorized variables were used in analysis.
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Relationship Between Gender, Medication Utilization, and Substance Use
The relationship between gender, medication utilization, and substance use was
evaluated by independent sample t-tests (see Table 8). Women were more likely than
men to be compliant with the medication Suboxone (t = -3.7, p<0.001). Men were
significantly more likely than women to use alcohol (t = 7.8, p<0.001), cannabis (t = 9.5
p<0.001), and opioids (t = 4.7, p<0.001) during treatment. Women were more likely to
use benzodiazepines (t = -10.9, p<0.001) and amphetamines (t = -9.3, p<0.001). There
was no significant difference between males and females in cocaine use (t = 2.7, p = .064;
see Table 8).
Table 8: Relationship between gender, medication utilization, and substance use.

Suboxone
Male
Female
Benzodiazepine
Male
Female
Alcohol
Male
Female
Cannabis
Male
Female
Amphetamine
Male
Female
Cocaine
Male
Female
Opioids
Male
Female

Mean

SD

t

p

58.9
60.1

17.5
16.6

-3.7

<0.001

6.9
9.7

12.8
14.2

-10.9

<0.001

13.5
10.7

19.6
17.3

7.8

<0.001

29.1
23.9

29.2
28.1

9.5

<0.001

3.4
5.5

10.2
13.5

-9.3

<0.001

14.3
13.2

20.8
20.7

2.7

0.064

13.5
12.1

15.0
14.5

4.7

<0.001

Relationship Between Age and Demographic Characteristics
The relationship between age and other demographic variables was evaluated via
t-tests (see Table 9). The between-group differences in mean age were significant for
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gender, race, PTSD/trauma, and CJS involvement. The mean age of males was higher
than females (t = 4.6, p = 0.038). Non-White patients were more likely than White
patients to be older (t =- 4.2, p<0.001). Patients who reported PTSD/trauma (t = -4.4,
p<0.001) and CJS involvement (t = 6.1, p<0.001) were also more likely to be older.
There was no significant relationship between mean age and ethnicity (t = 9.4, p = .172)
or anxiety (t = 1.0, p = 0.328).
Table 9: Relationship between age and demographic variables.

Gender
Male
Female
Race
White
Non-White
Ethnicity
Hispanic
Non-Hispanic
PTSD/Trauma
No
Yes
Anxiety
No
Yes
CJS Involvement
No
Yes

Mean

SD

t

p

39.1
38.2

10.6
10.3

4.6

0.038

38.1
40.8

10.4
12.3

-4.2

<0.001

40.9
38.0

10.0
10.4

9.4

0.172

38.5
39.5

10.7
9.9

-4.4

<0.001

38.6
38.8

10.7
10.2

-1.0

<0.328

39.1
37.8

10.9
9.6

6.1

<0.001

Note. CJS = criminal justice system.

Relationship Between Age and Counseling
The relationship between age and treatment utilization was analyzed via
independent t-tests (see Table 10). Given the smaller sample size for counseling scan data
(N = 669) the traditional alpha level (0.05) was used to examine the impact of counseling
with confirmatory (scan) data. Using the traditional level of alpha, there was a significant
relationship between age and counseling. Patients who had a history of counseling tended
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to be older than patients who did not. This relationship was found for all counseling
variables (patient report: t = -8.2, p<0.001; ever received counseling: t = -3.2, p = 0.002;
and evidence of current counseling: t = -2.5, p = 0.013).
Table 10: Relationship between age and counseling patient report.

Counseling Patient Report
No report
Report
Counseling Scan Ever
No scan
Scan
Counseling Scan Current
No scan
Scan

Mean

SD

t

38.1
39.8

10.5
10.5

-8.5

38.4
41.2

9.9
10.8

-3.2

38.7
41.3

10.0
11.1

-2.5

p
<0.001

0.002

0.013

Relationship Between Age and Treatment Utilization
The relationship between age and treatment utilization variables was analyzed by
computing the Pearson product-moment correlation coefficient (see Table 11). There was
a significant positive correlation between increased age and attendance at random
maintenance visits (r = 0.15, p<0.001), and maintenance visits (r = 0.13, p<0.001). There
was a significant negative correlation between increased age and “no shows” (r = -0.14,
p<0.001), tendency to reschedule visits (r = -0.04, p<0.001), and tendency toward care
interruptions (r = -0.07, p=<0.01). There was no significant correlation between increased
age and “other encounters” (r = 0.02, p = .052).
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Table 11: Relationship between age and treatment utilization.
r
# random maintenance visits
# maintenance visits
# “no show” visits
# rescheduled visits
# other encounters
# care interruptions
Total time in care
Time since the last visit

0.15***
0.13***
-0.14***
-0.04**
0.02
-0.07***
0.14***
-0.01

**p<.01. ***p<0.001.

Relationship between Age, Medication Utilization, and Substance Use
The relationships between age, medication utilization, and substance use were
analyzed via Pearson product-moment correlations (see Table 12). There was a
significant positive correlation between age and medication utilization (r = 0.09,
p<0.001). Older patients were more compliant with their OUD medication. Similarly,
older patients had higher rates of benzodiazepines (r = 0.11, p<0.001) and alcohol (r =
0.05, p<0.001). There was a significant negative correlation between age and use of
cannabis (r = -0.19, p<0.001), cocaine (r = -0.05, p<.001), and opioids (r = -0.12,
p<0.001). Younger patients were more often positive for these substances. There was no
significant correlation between age and use of amphetamines (r = -0.02, p = .097).
Table 12: Relationship between age, medication utilization, and substance use.
r
Medication Adherence
Suboxone
Substance Use
Benzodiazepine
Alcohol
Cannabis
Amphetamine
Cocaine
Opioids

.09***
.11***
.05***
-.19***
-.02
-.05***
-.12***

***p<0.001.
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Relationship Between Counseling and Demographic Characteristics
The relationship between counseling, gender, race, ethnicity, PTSD/trauma,
anxiety, and CJS involvement was evaluated via chi-square analysis (see Table 13). All
three measures of counseling were evaluated. Age was evaluated via correlation.
When examining patient-reported counseling, females were more likely to attend
counseling than males (χ2 = 119.9, p<.001). Those who identified as non-Hispanic (χ2 =
9.4, p = .001) reported more PTSD/trauma (χ2 = 240.5, p<.001), reported more anxiety (χ2
= 406.1, p<0.001), and CJS involvement (χ2 = 212.5, p<0.001) were significantly more
likely to report attending counseling to their provider. There was no significant
relationship between race and report of counseling (χ2 = 0.0, p = .898). There was also a
significant relationship between age and counseling based on patient report. Patients who
reported counseling to their provider (mean age = 39.8, SD = 10.5) were older (t = -8.5,
p<0.001) than patients who did not report counseling to their provider (mean age = 28.1,
SD = 10.5).
A similar relationship was found when examining confirmed report of ever
attending counseling and PTSD/trauma, anxiety, and history of involvement with CJS.
Patients positive for PTSD/trauma (χ2 = 10.8, p<.001), anxiety (χ2 = 11.1, p<.001), or CJS
involvement (χ2 = 12.1, p<.001) attended counseling more than those not positive on
these three variables. In contrast to the patient-reported variable, counseling attendance
when measured using confirmatory scans was unrelated to gender or ethnicity. Patients
with evidence of any counseling while in treatment were older than those without
counseling evidence (t = -3.0, p = 0.003).
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A similar pattern, when compared to ever attending counseling while in treatment
via confirmatory scale, was found when examining current counseling based on
confirmatory scans. The only difference was there was no relationship between current
counseling and report of PTSD/Trauma. Patients with evidence of current counseling
were older than those without current counseling confirmation (t = -2.3, p = 0.021).
Table 13: Relationship between counseling and demographic characteristics.
Counseling

Demographic

No
(%)

Patient Report
Yes
χ2
(%)

Gender
Male
68.2
Female
58.3
Race
White
63.9
Non-White
64.2
Ethnicity
Hispanic
68.5
Non-Hispanic
64.2
PTSD/Trauma
No
68.0
Yes
51.9
Anxiety
No
71.8
Yes
53.6
CJS History
No
68.3
Yes
54.0
**p<0.01. ***p<0.001.

Ever Confirmed
No
Yes
χ2
(%) (%)

Current Confirmed
No
Yes
χ2
(%) (%)

31.8
41.7

119.9***

73.7
71.9

26.3
28.1

0.3

83.3
81.5

16.7
18.5

0.4

36.1
35.8

0.0

73.8
72.4

26.2
27.6

0.0

83.0
79.3

17.0
20.7

0.3

31.5
35.8

9.4**

74.4
72.9

25.6
27.1

0.1

84.6
82.3

15.4
17.7

0.3

32.0
48.1

240.5***

76.1
63.0

23.9
37.0

10.8***

84.0
77.8

16.0
22.2

3.3

28.2
46.4

406.1***

78.0
66.4

22.0
33.6

11.1***

87.0
76.7

13.0
23.3

12.1***

31.7
46.0

212.5***

79.9
58.3

20.1
41.7

34.5***

86.5
74.1

13.5
25.9

15.7***

Relationship Between Counseling and Treatment Utilization
The relationship between patient-reported counseling and treatment utilization
was evaluated by independent t-tests (see Table 14). Again, all three counseling measures
were examined. Patients who reported counseling had more random maintenance visits (t
= -7.7, p<0.001), maintenance visits (t = -16.7, p = <0.001), frequency of “no show”
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visits (t = -2.4, p = 0.015), rescheduled visits (t = -9.3, p<0.001), and “other” encounters
(t = -13.7, p<0.001). Patients who were in counseling were also in care longer (t = -11.4,
p<0.001). When examining the smaller subset of patients with scanned confirmation of
ever having counseling while in treatment, there is also significant relationship between
many of the treatment utilization variables. In contrast to the patient report of counseling,
there was no relationship between counseling attendance and frequency of care
interruptions (t = -1.3, p = 0.178) or the amount of time since the last visit (t = 1.3, p =
0.182).
When examining confirmed current counseling, fewer treatment utilization
variables were significant based on counseling attendance. Patients who reported
counseling had more random maintenance visits (t = -5.0, p<0.001), maintenance visits (t
= -13.7, p = <0.001), rescheduled visits (t = -6.6, p<0.001), and “other” encounters (t = 10.0, p<0.001). Patients who were in counseling were also in care longer (t = -7.2,
p<0.001). There was no relationship between counseling attendance and frequency of “no
show” visits (t = -1.2, p = 0.884), frequency of care interruptions (t = -0.1, p = 0.888), or
the amount of time since the last visit (t = -0.6, p = 0.182).
When considering these relationships, it is important to understand that these
bivariate relationships do not account for total time in care. Since the treatment protocol
included a counseling requirement, patients who were not in counseling, might not be
still in treatment by choice.
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Table 14: Relationship between patient-reported counseling and treatment utilization.
Counseling
Patient Report
Mean SD
t
# random maint. visits
Counseling (No)
0.3
Counseling (Yes)
0.6
# maintenance visits
Counseling (No)
2.6
Counseling (Yes)
3.7
# “no show” visits
Counseling (No)
1.3
Counseling (Yes)
1.5
# rescheduled visits
Counseling (No)
1.1
Counseling (Yes)
1.5
# other encounters
Counseling (No)
3.0
Counseling (Yes)
3.6
# care interruptions
Counseling (No)
1.1
Counseling (Yes)
1.0
# total time in care
Counseling (No)
1.2
Counseling (Yes)
2.1
# time since last visit
Counseling (No)
0.7
Counseling (Yes)
0.5
*p<0.05. **p<0.01. ***p<0.001.

Ever Confirmed
Mean SD
t

Current Confirmed
Mean SD
t

0.6
0.6

-21.0***

0.3
0.7

0.5
0.7

-7.7***

0.4
0.7

0.6
0.7

-5.0***

1.5
1.0

-44.9***

2.7
4.1

1.4
-16.7***
0.7

2.8
4.0

1.5
0.7

-13.7***

0.8
0.9

-10.8***

1.4
1.5

0.8
0.8

-2.4*

1.4
1.5

0.8
0.8

-1.2

1.0
1.0

-24.1***

1.1
1.8

1.0
1.0

-9.3***

1.2
1.8

1.0
0.9

-6.6***

0.9
0.8

-35.2***

3.0
3.8

0.9
-13.7***
0.8

3.1
3.7

0.9
0.5

-10.0***

1.3
1.3

4.8***

1.1
1.2

1.3
1.4

1.1
1.1

1.4
1.5

-0.1

1.5
1.7

-27.0***

1.1
2.6

1.5
-11.4***
1.7

1.3
2.5

1.4
1.7

-7.2***

0.7
0.6

17.1***

0.7
0.6

0.7
0.5

0.7
0.7

0.7
0.7

-0.6

1.3

1.3

Relationship Between Counseling, Medication Utilization, and Substance Use
The relationship between counseling, medication adherence and substance use
were evaluated by independent sample t-tests (see Table 15). Again, all three counseling
measures were examined. When examining all three counseling measures, patientreported counseling present in the EHR confirmed counseling ever in treatment and
confirmed current counseling, there was a significant relationship between counseling
and medication adherence. Patients in counseling were more adherent to medication than
patients not in counseling (EHR report: t = -25.9, p<0.001; confirmed ever: t = -6.5,
p<0.001; confirmed current: t = -4.8, p<0.001).
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Analysis examining EHR patient report also revealed significant relationships
between counseling and all substance use variables. Those who reported having attended
counseling had higher mean levels of benzodiazepines (t = -8.1, p<0.000) and
amphetamines (t = -8.5, p<.000), yet lower levels of alcohol (t = 2.6 p = .012), cannabis (t
= 3.8, p<0.000), cocaine (t = 8.1, p<.000), and opioids (t = 25.5, p<0.000).
When examining the subset of patients using scanned confirmation data, there
was no relationship between counseling and benzodiazepine, alcohol, cannabis, or
amphetamine use for both evidence ever in treatment (t = -1.1, p = 0.279; t = 0.5, p =
0.616; t = 1.1, p = 0.259; t = -1.0, p = 0.318, respectively) or currently in treatment (t = 1.3, p = 0.194; t = 0.7, p = 0.512; t = 0.5, p = 0.584; t = -0.2, p = 0.906, respectively).
There was, however, significant relationships between counseling ever while in treatment
and cocaine and opioids (t = 4.3, p<0.001; t = 5.1, p<0.001, respectively) or currently in
treatment (t = 2.7, p = 0.007; t = 3.0, p = 0.003, respectively).

Table 15: Relationship between counseling, medication utilization, and substance use.
Patient Report
Mean SD
t
Medication Adherence
Counseling (No)
Counseling (Yes)
Benzodiazepine
Counseling (No)
Counseling (Yes)
Alcohol
Counseling (No)
Counseling (Yes)
Cannabis
Counseling (No)
Counseling (Yes)
Amphetamine
Counseling (No)
Counseling (Yes)

56.8
64.1

Counseling
Ever Confirmed
Mean SD
t

Current Confirmed
Mean SD
t

19.6
58.7
-25.9***
10.3
64.8

17.8
6.2

-6.5***

59.6
64.2

17.0
6.9

-4.8***

7.3
9.4

13.7
13.0

-8.1***

8.3
9.5

13.6
13.0

-1.1

8.3
10.1

13.3
13.8

-1.3

12.6
11.7

19.5
17.1

2.6**

12.5
11.7

19.5
16.7

0.5

12.5
11.2

19.2
16.4

0.7

27.7
25.6

29.3
28.0

3.8***

27.1
24.3

28.6
27.8

1.1

26.6 28.4
25.0 28.2

0.5

3.5
5.6

10.9
12.9

-8.5***

4.1
5.1

11.7
11.8

-1.0
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4.3
4.5

12.0
10.6

-0.2

Cocaine
Counseling (No)
15.0
Counseling (Yes)
11.9
Opioids
Counseling (No)
15.3
Counseling (Yes)
8.8
*p<0.05. **p<0.01. ***p<0.001.

16.2
18.4

8.1***

15.4
9.1

22.2
14.1

4.3***

14.4
9.9

21.5
14.7

2.7**

16.2
10.8

25.5***

13.7
8.6

14.6
10.3

5.1***

12.9
9.4

14.3
10.6

3.0**

Relationship Between Race, Ethnicity, and Other Demographic Characteristics
Most bivariate analyses regarding race and ethnicity have been provided above.
Given the low rate of variability in both race (95.6% White) and ethnicity (85.1% nonHispanic), additional analyses were not performed.
Reliability of Patient Report of Counseling
The reliability of self-reported individual counseling data was evaluated by the
presence of counseling confirmation (see Table 16). To determine whether a relationship
existed between individual counseling reported by patients in progress notes, scans
confirming current attendance at individual counseling, and scans confirming patients
had ever been in individual counseling, chi square analyses were done.
Results of the analysis showed there was a significant difference between patient
report of counseling and patients with scanned confirmation of counseling. Among the
patients who indicated that they were currently in counseling, scanned evidence was
available for only 33% of the patients. The significant difference suggests that the patient
report of counseling in the EHR is not reliable.

Table 16: Reliability of patient-reported counseling.

Current Confirmation
Past Confirmation

No
Yes
No
Yes

Patient Report
No
Yes
336
216
10
107
292
196
54
127
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χ2

p

105.8

<0.001

47.6

<0.001

Analysis of Study Aims
Due to the lack of reliability in patient-reported data in the EHR, only confirmed
counseling data was used in the multivariate analyses. According to the a priori power
analyses, 787 patients were required to identify a small effect size (f = 0.1). Using a
sample size of 669, two groups and six covariates, a small effect size (0.16) can still be
identified as significant. Thus, there would be minimal risk of Type II error. Covariates
included in multivariate analyses include gender (male/female), age, PTSD (yes/no),
anxiety (yes/no), history of involvement with the CJS (yes/no), and total time in care.
Total time in care is included as a covariate for the following treatment utilization
variables: number of random maintenance visits, number of maintenance visits, number
of no-show visits, number of rescheduled visits, number of other encounters, and number
of care interruptions. Total time in care is included as the rates of these variables increase
as a patient is in care for longer durations. Total time in care will not be used as a
covariate when the treatment utilization variables examined are total time in care, time
since the last visit, and retention.
Ethnicity and race were not included in the analyses due to the large number of
missing data and the homogeneity of variance, as discussed above. Approximately one
quarter of the sample (25.4%) was missing data for race and 20.9% were missing
information on ethnicity.
Sample Comparison
Prior to analysis of study aims, patients included in the analysis sample, patients
whose data was evaluated via confirmatory counseling scans were compared to patients
not included in the analysis. Comparisons were performed on all dependent variables
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(treatment utilization, medication utilization, drug use). The only difference identified
between patients included in the analysis and patients not included in the analyses was on
time since the last visit. Patients not included had been seen more recently in care (t = 2.12, p = 0.030). As there is a large difference in sample size, this analysis was confirmed
by non-parametric analysis (Mann-Whitney U). There were no differences in the
parametric and non-parametric tests.

Table 17: Sample comparison (included and not included in aims analyses).

Treatment Utilization
# random maintenance visits
Not included
Included
# maintenance visits
Not included
Included
# “no show” visits
Not included
Included
# rescheduled visits
Not included
Included
# other encounters
Not included
Included
# care interruptions
Not included
Included
# total time in care
Not included
Included
# time since last visit
Not included
Included
Medication Utilization
Not included
Included
Substance Use
Benzodiazepine
Not included
Included

Mean

SD

t

p

0.4
0.4

0.6
0.6

0.4

0.689

3.0
3.0

1.5
1.4

-1.0

0.297

1.4
1.4

0.8
0.8

-1.4

0.167

1.2
1.3

1.0
1.0

-1.0

0.331

3.2
3.2

0.9
0.9

-0.7

0.497

1.1
1.1

1.3
1.4

-0.6

0.520

1.5
1.5

1.6
1.5

0.3

0.728

0.6
0.7

0.7
0.7

-2.2

0.030

59.4
60.4

17.2
15.7

-1.5

0.147

8.0
8.6

13.5
13.4

-1.1

0.268
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Alcohol
Not included
Included
Cannabis
Not included
Included
Amphetamine
Not included
Included
Cocaine
Not included
Included
Opioids
Not included
Included

12.3
12.3

18.7
18.7

0.1

0.954

27.0
26.3

28.9
28.4

0.6

0.540

4.3
4.3

11.7
11.7

-0.1

0.920

13.9
13.6

20.8
20.5

0.3

0.787

13.0
12.3

14.9
13.7

1.1

0.278

Analysis of Aim 1
Aim 1. What is the relationship between treatment utilization, medication utilization, and
opioid use in a sample of individuals with opioid use disorder receiving medication
treatment?
H1a: Patients with higher rate of random maintenance visit compliance will have
increased medication utilization.
H1b: Patients with a higher rate of maintenance visit compliance will have increased
medication utilization.
H1c: Patients with a lower rate of “no show” visits will have increased medication
utilization.
H1d: Patients with longer total time in care will have increased medication utilization.
H1e: Patients with a lower rate of rescheduled visits will have increased medication
utilization.
H1f: Patients with a lower rate of other encounters will have increased medication
utilization.
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H1g: Patients with a lower rate of care interruptions will have increased medication
utilization.
H1h: Patients with less time since the last visit will have increased medication
utilization.
H1i: Patients with a higher rate of random maintenance visit compliance will have
decreased opioid use.
H1j: Patients with a higher rate of maintenance visit compliance will have decreased
opioid use.
H1k: Patients with a lower rate of “no show” visits will have decreased opioid use.
H1l: Patients with longer total time in care will have decreased opioid use.
H1m: Patients with a lower rate of rescheduled visits will have decreased opioid use.
H1n: Patients with a lower rate of other encounters will have decreased opioid use.
H1o: Patients with a lower rate of care interruptions will have decreased opioid use.
H1p: Patients with less time since the last visit will have decreased opioid use.
H1q: Patients with increased medication utilization will have decreased opioid use.
To examine the relationship between treatment utilization variables and
medication utilization, and opioid use, partial correlations were performed (see Table 18).
Due to the smaller sample size, the traditional level of significance (p<0.05) was used to
evaluate statistical significance. Results of the partial correlations showed a positive
relationship between the number of maintenance visits, random maintenance visits,
rescheduled visits, other encounters, total time in care, retention, and medication
utilization after covariate control. Further, there was a negative relationship between the
number of care interruptions and time since last visit and medication utilization. Overall,
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results suggest that patients who are engaged in treatment for OUD are more likely to
take their medication.
When examining opioid use, results revealed that higher rates of treatment
compliance were related to lower rates of opioid use. Patients with more maintenance
visits and more random maintenance visits had fewer positive opioid test results. Patients
with more care interruptions and more “no show” visits, in contrast, had more frequent
positive opioid tests. Patients who had been in care longer and had increased retention
had fewer positive opioid results. These findings also support the hypothesis that
increased treatment utilization is effective in reducing opioid use among patients in OUD
treatment.
Table 18: Relationship between treatment utilization, medication utilization,
and opioid use.

Treatment Utilization
# maintenance visitsa
# random maintenance visitsa
# rescheduled visitsa
# other encountersa
# care interruptionsa
# “no show” visitsa
Total time in careb
Time since the last visitb
Retentionb

Medication
Utilization

Opioid Use

0.56***
0.14***
0.17***
0.12**
-0.16***
0.03
0.27***
-0.21***
0.16***

-0.25***
-0.19***
-0.03
-0.01
0.28***
0.14***
-0.37***
0.27***
-0.21***

**p<0.01. ***p<0.001.
a
Covariates: age, gender, PTSD/Trauma, CJS, Anxiety, and total time in care.
b
Covariates: age, gender, PTSD/Trauma, CJS, Anxiety

Analysis of Aim 2
Aim 2. Determine if medication utilization mediates the relationship between treatment
utilization and opioid use in patients receiving medication treatment.
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H2a: Medication utilization will mediate the relationship between rate of random
maintenance visit compliance and opioid use.
H2b: Medication utilization will mediate the relationship between rate of maintenance
visit compliance and opioid use.
H2c: Medication utilization will mediate the relationship between rate of “no show”
visits and opioid use.
H2d: Medication utilization will mediate the relationship between total time in care
and opioid use.
H2e: Medication utilization will mediate the relationship between rate of rescheduled
visits and opioid use.
H2f: Medication utilization will mediate the relationship between rate of other
encounters and opioid use.
H2g: Medication utilization will mediate the relationship between rate of care
interruptions and opioid use.
H2h: Medication utilization will mediate the relationship between time since the last
visit and opioid use.
To examine if medication utilization mediated the relationship between treatment
utilization and opioid use, regression analyses were used. In this analysis, a separate
regression was performed using each of the treatment utilization variables as a predictor.
In each regression, all covariates were included in the first step and medication utilization
was included in the second step. To examine mediation, the weight of the Beta coefficient
for the treatment utilization predictor between Model 1 and 2 was compared (see Table
19).
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Table 19: Evaluation of medication utilization as a mediator.
Opioid Use
Model 1
Model 2
β
β
Treatment Utilization
# maintenance visits

-.37***

-.13*

# random maintenance visits
-.22***
-.16***
# rescheduled visits
-.06
.01
# other encounters
-.04
.02
# care interruptions
.26***
.21***
# “no show” visits
.12**
.13***
Retention
-.21***
-.16***
Total time in care
-.39***
-.28***
Time since the last visit
.19***
.14***
**p<0.01. ***p<0.001.
Note. Model 1 provides Beta prior to entry of medication utilization.
Model 2 provides Beta after inclusion of medication utilization.

None of the analyses suggested full mediation. However, in several analyses
where there was a significant relationship between treatment utilization and opioid use,
the magnitude of some treatment utilization variables (maintenance visits, random
maintenance visits, time in care, and retention) was reduced when medication adherence
was added to the regression model. The only exception was for the number of “no show
visits” where there is no evidence of mediation. Thus, it does appear that medication
utilization partially mediates the relationship between treatment utilization and opioid
use. In other words, the positive impact of treatment compliance on reduced opioid use is
at least partially due to medication utilization.
Analysis of Aim 3
Aim 3. Examine the impact of current and prior counseling on treatment utilization,
medication utilization, substance use, and treatment retention.
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H3a: There will be no difference in rate of random maintenance visit compliance
between patients who are currently in counseling and those who are not.
H3b: There will be no difference in rate of random maintenance visit compliance
between patients who have previously been in counseling and those who are not.
H3c: There will be no difference in rate of maintenance visit compliance between
patients who are currently in counseling and those who are not.
H3d: There will be no difference in rate of maintenance visit compliance between
patients who have previously been in counseling and those who are not.
H3e: There will be no difference in rate of “no show” visits between patients who are
currently in counseling and those who are not.
H3f: There will be no difference in rate of “no show” visits between patients who have
previously been in counseling and those who are not.
H3g: There will be no difference in total time in care between patients who are
currently in counseling and those who are not.
H3h: There will be no difference in total time in care between patients who have
previously been in counseling and those who are not.
H3i: There will be no difference in rate of rescheduled visits between patients who are
currently in counseling and those who are not.
H3j: There will be no difference in rate of rescheduled visits between patients who
have previously been in counseling and those who are not.
H3k: There will be no difference in rate of other encounters between patients who are
currently in counseling and those who are not.
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H3l: There will be no difference in rate of other encounters between patients who have
previously been in counseling and those who are not.
H3m: There will be no difference in rate of care interruptions between patients who
are currently in counseling and those who are not.
H3n: There will be no difference in rate of care interruptions between patients who
have previously been in counseling and those who are not.
H3o: There will be no difference in time since last visits between patients who are
currently in counseling and those who are not.
H3p: There will be no difference in time since last visit between patients who have
previously been in counseling and those who are not.
H3q: There will be no difference in medication utilization between patients who are
currently in counseling and those who are not.
H3r: There will be no difference in medication utilization between patients who have
previously been in counseling and those who are not.
H3s: There will be no difference in opioid use between patients who are currently in
counseling and those who are not.
H3t: There will be no difference in opioid use between patients who have previously
been in counseling and those who are not.
H3u: There will be no difference in treatment retention between patients who are
currently in counseling and those who are not.
H3v: There will be no difference in treatment retention between patients who have
previously been in counseling and those who are not.
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To examine the impact of counseling on treatment utilization, medication
utilization, substance use, and treatment retention, linear regression and logistic
regression were utilized. All covariates were entered in the first step with the predictor
entered in the second step.
Table 20: Impact of current and past counseling on treatment utilization, medication
utilization, and substance use.
Counseling
Current
Ever
Treatment Utilization
# maintenance visits
.10***
-.13***
# random maintenance visits
.04
.06
# rescheduled visits
.08*
.13***
# other encounters
.04
.09*
# care interruptions
-.02
.03
# “no show” visits
-.05
-.05
Retentiona
-.14
.29
Total time in care
.22***
.37***
Time since the last visit
.06
-.02
Medication Utilization
Suboxone
.07
.13***
Substance Use
Benzodiazepine
.00
-.02
Alcohol
-.04
-.04
Cannabis
-.02
-.04
Amphetamine
-.02
.02
Cocaine
-.10*
-.16***
Opioids
-.07
-.14***
*p<0.05. **p<0.01. ***p<0.001.
a
Note. Value is B (unstandardized coefficient) from logistic regression.

Although a history of attending prior counseling while in treatment had a positive
impact on medication utilization, there was not a significant relationship between
currently attending counseling and medication utilization. Current counseling attendance
was only related to higher rates of maintenance visits, increased total time in care, higher
rates of rescheduled visits, and reduced cocaine use. Importantly, current counseling
attendance was not related to either opioid use or treatment retention.
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Patients who had been in counseling at some point in treatment had lower rates of
maintenance visits, were in care longer, had higher rates of rescheduled visits, and more
overall treatment encounters. In addition, patients who had been in counseling at some
point in treatment, but not currently, had higher rates of medication utilization and
reduced cocaine and opioid use. Thus, although prior history of counseling appears to
have a positive impact on OUD treatment outcomes, current counseling had little impact
on OUD treatment variables.
Analysis of Aim 4
Aim 4. To examine the comparative effectiveness of type of psychosocial treatment on
medication utilization, treatment utilization, and opioid use in a sample of patients
receiving medication treatment.
This aim could not be examined given the homogeneity in counseling services
identified in the EHR.
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CHAPTER 5
DISCUSSION
This chapter discusses the findings of the study, implications for practice,
limitations, and questions for future research. The main aim of this study was to examine
the impact of counseling on several treatment utilization variables, medication adherence,
substance use, and retention in patients in treatment for OUD.
Some of the findings of this study will assist in patient care. For example, the
results of this study found that patients with increased rates of treatment utilization were
more likely to utilize medication treatment and demonstrate reduced opioid use. In
addition, higher rates of treatment utilization were related to reduced opioid use. Further,
patients with more frequent interruptions in OUD treatment were more likely to test
positive for opioids.
Women in OUD treatment were more likely to have experienced PTSD/trauma,
and anxiety, while males were more likely to have CJS involvement. Women in this
study were more likely to be retained in care, and were in treatment for a longer length of
time than males. In addition, older patients were more likely to utilize their medication
than younger patients were; however, they were also more likely to use benzodiazepines
and alcohol.
There was very little evidence that counseling during OUD treatment had a
positive impact on treatment utilization. And there was no evidence that counseling while
active in treatment had an impact on medication utilization or opioid use. Although
counseling may have some benefit for some patients in OUD treatment, the findings of
the present study do not support mandating counseling during OUD treatment.
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Relationship Between Gender and Demographic Variables
The findings of bivariate analyses of gender and demographic variables suggest
that females were more likely to identify as non-Hispanic and to report having
experienced PTSD/trauma and anxiety, while males were more likely to have
experienced involvement with the CJS. The analyses found no significant relationship
between gender and identifying as White.
Given the lack of diversity among women in the study population, the question
arises as to whether persons of diverse backgrounds have adequate access to treatment for
OUD. A recent study based on nationally representative data from ambulatory medical
care surveys found that White persons, those who can pay out of pocket or have private
insurance, are more likely to receive opioid treatment with buprenorphine (Lagisetty,
Ross, Bohnert, Clay, & Maust, 2019). Very often, demographics determine the choice of
medication rather than the extent and severity of an individual’s OUD (Manhapra,
Quinones, & Rosenheck, 2016).
It is noteworthy that women in medication treatment for OUD were more likely to
have experienced PTSD/trauma and anxiety. This is consistent with previous research
(Back et al., 2011; A. Campbell et al., 2018; Greenfield, Back, Lawson, & Brady, 2010;
Huhn, Berry, & Dunn, 2019; S. Ling, Mangaoil, Cleverley, Sproule, & Puts, 2019). In
fact, A. Campbell et al. (2018) and Huhn et al. (2019) recommend the utilization of
gender-specific interventions for women with OUD, co-occurring mental health disorders
and trauma in order to address the unique needs of this population. Women were more
likely than men to have scans confirming current and prior counseling in the EHR. Given
that PTSD/trauma and co-occurring mental health disorders can cause severe symptoms
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that may interfere with daily functioning, one would expect these patients to have sought
counseling.
In contrast, males were more likely to have been involved with the CJS. It is
noteworthy that patients who were involved with the CJS were also more likely to have
confirmation scans of present and prior counseling in their EHR. Often persons in the
CJS enter diversion programs that permit them to seek treatment as an alternative to
incarceration (SAMHSA, 2019b). Furthermore, it is highly recommended that a
successful collaborative relationship between treatment systems and the CJS exist since
treatment must be individualized to the CJS and the client’s stage in recovery (SAMSHA,
2005). This may explain, in part, the reason these patients were more likely to be in
current or prior counseling.
Relationship Between Gender, Counseling, Treatment Utilization, and Substance
Use
In relation to gender and treatment utilization, women were more likely than men
to attend random visits, other encounters, and spend more time in care, which are
indicators of treatment utilization. Previous research suggests women are more likely to
be retained in treatment than their male counterparts (Saxon et al., 2013; Weinstein et al.,
2017). Conversely, women were more likely to “no show” for visits and reschedule visits,
while males were more likely to have treatment interruptions. Weinstein et al. (2017)
caution that although women may have better retention in outpatient treatment for OUD,
there remains a great deal of stigma that prevents women from fully engaging in
treatment. In addition, women may lack childcare and are concerned with losing custody
of their children should their history of opioid use be revealed (Tuchman, 2010). They
demonstrate more economic vulnerability, may live with an abusive partner, or are single
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mothers with children. They also are more likely to live with a partner who is using
substances (Bawor et al., 2015). These factors may result in more treatment interruptions
for women, which may explain, increased “no shows” and the rescheduling of treatment
visits.
With respect to medication compliance and substance use, women were more
likely to adhere to medication treatment, yet test positive for benzodiazepines and
amphetamines, a finding consistent with previous research (Back et al., 2011). Evidence
exists that women are more vulnerable to the rewarding effects of stimulants and that
estrogen is possibly a factor in this sensitivity (Anker & Carroll, 2011; NIDA, 2018f).
Also, women are more at risk for anxiety (A. Campbell et al., 2018; NIMH, 2016) and
often are prescribed anti-anxiety medications, which in turn increases access and misuse
(NIDA, 2018f). Men, on the other hand, were more likely to test positive for alcohol,
cannabis, and opioids during medication treatment for OUD. This is consistent with
previous research on substance abuse in males (A. Campbell et al., 2018; NIDA, 2018f;
SAMHSA, 2017). Several researchers have suggested that since there are a number of
differences in treatment outcomes for women that are not well understood, more research
is needed in this area (Back et al., 2011; Huhn et al., 2019).
Influence of Age on Patient Characteristics and OUD Outcome Variables
There were significant relationships between age and several patient
characteristics including gender, race, PTSD/trauma, and CJS involvement. Males and
non-Whites were more likely to be older. Interestingly, older patients were more likely to
have confirmation scans of current and prior counseling. Perhaps, along with additional
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years comes an increased risk of major life events that may have necessitated counseling
at one time or another.
In terms of treatment utilization, attendance at random maintenance and
maintenance visits increased with age as well. Increased age was related to fewer
treatment interruptions, while younger patients were more likely to have treatment
interruptions. Young adults ages 18–25 are known to be the largest group to abuse
prescription opioids, stimulants, and anti-anxiety agents (CDC, 2018). Future studies
aimed at identifying specific interventions that will better engage young persons in opioid
use treatment would be useful since the problem of opioid use is rapidly increasing
among this population.
The findings suggest that older individuals are more likely to utilize their
medication. In addition, the use of benzodiazepines and alcohol increased with age, while
the use of cannabis, cocaine, and opioids was more common in younger patients. In fact,
the misuse of tranquilizers and sedatives has been increasing among older adults in recent
years and presents a number of significant dangers associated with it. Olfson, King, and
Schoenbaum (2015) conducted a retrospective descriptive study on a prescription
database that included 60% of all retail pharmacies in the United States. Their findings
suggest that despite risks associated with long-term benzodiazepine use, it remains
common in older adults. Furthermore, among the 5.2% of adults aged 18–80 who used
benzodiazepines in 2008, the largest percentage (8.7%) occurred among 65–80 year olds.
Further, Schepis and McCabe (2019) used data from the 2009–2012 National Survey on
Drug Use and Health, and found that older adults (ages 50 and older) had increased
misuse of tranquilizers and sedatives and associated negative consequences (suicidal
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ideation). Their findings suggest that tranquilizer/sedative misuse has a unique pattern
among older adults and is largely understudied.
Relationship Between Patient Characteristics and Counseling
Patients who identified as non-Hispanic, had a past history of PTSD/trauma,
anxiety, and CJS involvement were more likely to be in current and prior counseling.
Older patients were also more likely to have confirmation of current and prior counseling.
There was no relationship between race and current or prior counseling. As noted
previously, there was minimal variance in race. Patients with PTSD/trauma, anxiety, and
CJS involvement were more likely to have scans confirming prior counseling. No
significant relationship was found between gender and current or prior counseling.
Analysis of Study Aims
Aim 1
The purpose of this aim was to examine the relationship between treatment
utilization (maintenance visits, random maintenance visits, rescheduled visits, other
encounters, care interruptions, “no show” visits, total time in care, time since last visit,
and retention) and medication utilization and opioid use. It was hypothesized that patients
with higher rates of treatment utilization would be more likely to utilize their medication.
The findings suggest that patients who had increased maintenance visits were more likely
to utilize medication, be retained in treatment, and have reduced opioid use. The
hypotheses were supported by the results (Table 21). This finding highlights the
importance of engagement in treatment in order to promote medication adherence, which
is essential in preventing relapse. The importance of Suboxone utilization (and other
medications for OUD) in combating the opioid crisis cannot be overstated. Its
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effectiveness in reducing opioid use is widely known (Fiellin et al., 2015; Hser et al.,
2014; Kamien, Branstetter, & Amass, 2008; Mariolis, Bosse, Martin, Wilson, & Chiodo,
2019; Rosenthal et al., 2013).
Given the importance of OUD treatment and medication utilization, it is
concerning that both are widely underutilized due to poor access. In order to increase
access, there has been movement toward getting physicians in primary care and other
medical settings to provide office-based treatment, along with Suboxone and other
medications for OUD. Offering treatment in primary care settings has been shown to
reduce attrition in opioid use treatment. Presnall, Wolf, Brown, Beeler-Stinn, and Grucza
(2019) conducted a study in which they found the utilization of medication treatment
reduced dropout rates, OUD-related ED visits and hospitalizations, and treatment in
office-based settings was even more effective in reducing negative outcomes related to
OUD.
Additionally, the results of recent studies suggest that treatment utilization and
buprenorphine are effective for persons with OUD and co-occurring chronic diseases. In
a recent retrospective cohort study designed to quantify the effect of buprenorphine on
adherence to five therapeutics classes of medications, the researchers found
administration of buprenorphine in office-based treatment was associated with greater
odds of adherence to antilipids, antiepileptics, and antidepressants (Chang, Daubresse,
Saloner, & Alexander, 2019). They concluded that using medication treatment for OUD
may increase adherence to medications for many chronic diseases and that this is
especially important given the high rates of comorbidities in populations with OUD.
Thus expanding measures to further engage patients in treatment for OUD, not only
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improves medication adherence, but holds promise for patients with OUD and cooccurring medical conditions. It is concerning, however, that only one third of outpatient
treatment centers provide treatment for OUD, chronic diseases, as well as infectious
diseases (Jones et al., 2019). Thus, reduced access is a barrier for OUD patients with cooccurring medical and infectious diseases as well.
Table 21: Summary table of partial correlations between treatment utilization,
medication utilization, and opioid use.
Medication
Utilization Opioid Use
Treatment Utilization
# maintenance visits
+
# random maintenance visits
+
# rescheduled visits
+
# other encounters
+
# care interruptions
+
# “no show” visits
+
Total time in care
+
Time since the last visit
+
Retention
+
+ or - = a relationship between treatment compliance or drug use and IV’s.
Unless otherwise noted, +/- apply to all variables.

Aim 2
The objective of Aim 2 was to determine if medication utilization mediated the
relationship between treatment utilization and opioid use in patients receiving medication
treatment. It was hypothesized that medication utilization would mediate the relationship
between treatment utilization and use of opioids. As stated earlier, although none of the
results suggested full mediation, medication utilization had a very small impact on
increasing maintenance visits; however, the effect size was very small (Table 22). The
hypotheses for this aim were not supported by the results. Although treatment utilization
and opioid use were not mediated by medication utilization, the use of opioids during
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OUD treatment is associated with early treatment dropout and poor treatment outcomes,
and therefore, continues to be a target of OUD treatment (M. Campbell, Kolodner,
Spencer, & DuPont, 2016).
In the recent M. Campbell et al. study (2016), the researchers found that
nonprescribed opioid and drug use during maintenance treatment is highly correlated
with lowered retention and risk of early treatment termination. Patients in maintenance
treatment with at least one positive drug test left treatment 6 months sooner, on average,
than those with no positive drug tests and were twice as likely to leave without
completing continuing care (87% to 42%; M. Campbell et al., 2016).
The Ronquest, Willson, Montejano, Nadipelli, and Wollschlaeger (2018) study
found that remaining on buprenorphine (BUP) after the discontinuation of OUD
treatment continues to prevent relapse and reduce medical costs in patients. They
determined that BUP adherence in the 12 months following treatment for OUD reduced
the odds of relapse and unadjusted medical costs for patients. After adjustment, total
costs of adherent patients with commercial insurance were significantly lower than nonadherent patients (Ronquest et al., 2018). The results of this current study underscore the
importance of medication adherence in reducing relapse and its negative health
consequences.
Aim 3.
The objective of this aim was to examine the impact of current and prior
counseling on treatment utilization, medication utilization, and opioid use. The findings
indicate there was not a significant relationship between current attendance at counseling
during OUD treatment, and medication utilization or opioid use. Prior counseling had a
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positive impact on treatment utilization (total time in care), medication utilization,
reduced cocaine use, and reduced opioid use; however, the effect sizes were very small.
The findings suggest that while current counseling may have some benefit for some
patients in OUD treatment, the results of this study found no evidence that supports the
current policy that requires patients to be in counseling during treatment.
Table 22: Summary table of relationship between current and prior counseling on
treatment utilization, medication utilization, and substance use.
Counseling
Current
Ever
Treatment Utilization
# maintenance visits

+

-

# random maintenance visits
# rescheduled visits
+
+
# other encounters
+
# care interruptions
# “no show” visits
Retention
Total time in care
+
+
Time since the last visit
Medication Utilization
Suboxone
+
Substance Use
Benzodiazepine
Alcohol
Cannabis
Amphetamine
Cocaine
Opioids
+ or - = a relationship between treatment compliance or drug use and IV’s.
Unless otherwise noted, +/- apply to all variables.

Results of prior studies on the impact of counseling in OUD treatment are mixed.
For example, Moore et al. (2016) conducted a secondary analysis of a 24-week
randomized trial of physician management or physician management plus cognitive
behavioral therapy (CBT) offered along with BUP in a primary care setting to OUD
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patients and examined whether outcomes differed between the groups. While opioid
abstinence and retention did not differ according to opioid use group (heroin or
prescription opioids), the type of opioid moderated the effect of CBT on negative urine
samples for all drugs. Prescription opioid use patients assigned to physician management
combined with CBT had more than twice the mean amount of abstinence from all
substances. The researchers suggest that closer examination of additional factors that
predict response to CBT and other behavioral interventions may shed light on response to
various interventions. The results suggest that prescription opioid patients responded
better to counseling, specifically physician management and CBT, than heroin users. This
is an important consideration in the development of treatment plans for prescription
opioid patients and heroin users in clinical practice.
Conversely, a well-known randomized controlled trial conducted by W. Ling et
al. (2013), compared the effectiveness of combining BUP with four types of behavioral
treatments: CBT; contingency management (CM); both CBT and CM; and no behavioral
treatment. The primary outcome was urine tests for opioid use; additional outcomes
included retention, withdrawal symptoms, craving, other drug use, and adverse events.
The researchers found no differences among the groups in opioid use. They concluded
there was no clear evidence that CBT or CM reduce opioid use when combined with
BUP and medical management (W. Ling et al., 2013).
Carroll and Weiss (2017) conducted a systematic review of randomized controlled
trials in order to examine what constitutes appropriate counseling in OUD treatment.
They reported that four key studies demonstrated no benefit from adding counseling to
BUP plus medical management, and four studies identified some benefit for specific
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types of behavioral counseling and contingency management (CM). They concluded that
while high-quality medical management works for some patients with OUD, retention
rates at 6 months seldom reached above 50%. Additionally, poor treatment outcomes
were associated with dropping out of treatment. They suggested more evidence is
required to determine for whom medical management is sufficient, and to develop
strategies to better retain individuals in OUD treatment with BUP (Carroll & Weiss,
2017).
Additionally, Fiellin et al. (2013) conducted a 24-week randomized controlled
trial with 141 patients in primary care, office-based buprenorphine/naloxone treatment to
determine the impact of behavioral therapy on treatment outcomes. Patients were
randomly assigned to receive physician management or physician management plus
CBT. The primary outcomes were self-reported opioid use, abstinence from opioid use
determined by urine tests. The two treatment conditions had similar effectiveness in
reducing self-reported opioid use. The researchers reported that among subjects in the
study sample, the effectiveness of the two interventions did not differ significantly
(Fiellin et al., 2013).
Finally, Sofuoglu, DeVito, and Carroll (2019) conducted a nonsystematic review
in order to examine OUD treatments, key pharmacological and behavioral interventions,
their mechanism of action, effectiveness, clinical practice guidelines. They also wanted to
identify specific approaches to co-occurring medical conditions during OUD treatment.
They concluded that while medication treatment is an effective first-line approach to
OUD for patients with psychiatric comorbid conditions, it is more effective when
combined with behavioral interventions. This permits evaluation and monitoring of
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psychiatric symptoms that can potentially reduce the effectiveness of medications for
OUD (Sofuoglu et al., 2019). In addition, the researchers recommended future studies
that examine treatments for patients with OUD and psychiatric conditions.
The results of the current study do not provide evidence for policy that mandates
counseling while in treatment. Requiring counseling during OUD likely reduces access to
treatment and presents a barrier for patients who may benefit from medication alone.
Given that attending counseling presents a hardship for some patients, due to lack of
resources such as transportation, and childcare, among others, clinicians should question
if counseling is necessary. Restriction of care might be more harmful than not receiving
counseling during OUD treatment. In addition, in the future, it also might be beneficial to
utilize other mechanisms of evaluating the influence of counseling on care such as the
level of patient functioning (e.g., maintaining a stable home, employment, avoidance of
criminal behavior, and successful management of medical and mental health conditions)
(Carroll & Weiss, 2017). Other factors to take into account are a patient’s motivation,
financial resources, family support, and severity of opioid disorder and co-occurring
medical and mental health illnesses. Requiring all patients in OUD treatment to attend
counseling carries the serious risk of becoming a barrier to treatment, thereby reducing
access to care for those who need it.
In summary, the findings of Aim 3 suggest that attending counseling during
treatment for OUD has minimal impact on treatment utilization, does not improve
medication utilization, and does not reduce opioid use. Requiring patients to attend
counseling in order to receive OUD treatment is potentially harmful in that it creates a
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barrier to treatment, increases the treatment burden, and limits access to patients who
need it.
Application to Theory
As explained in Chapter 2, the complexity of OUD precludes it from being clearly
understood from the perspective of a single theory or conceptual framework. This study
utilized two theoretical viewpoints to grasp the complex nature and progression of OUD.
First, OUD was examined from the viewpoint that it is both a neurobiological illness and
a chronic disease that requires continuous management by patients, nurses, and HCPs
over long periods, or perhaps over the course of a lifetime. As with other chronic
diseases, OUD presents with periods of relapse and remission, and has no cure. Goals of
treatment should include self-management and an individualized, patient-oriented plan of
care to assist patients to cope effectively with urges and reduce the potential for relapse.
First, the Neuman Systems Model provided a theoretical framework for
comprehending OUD in the context of multiple contributing factors. The NSM is a theory
that puts forth the notion that individuals are open systems interacting with one another
and the environment (Neuman, 1982). The theory suggests that, in order to maintain
health, an individual must continually adapt to its environment. Should an individual face
undue stress, the balance and stability of an “organism” is threatened; therefore,
adjustment to stressors is a continuous and active process. The variables that determine
successful adaption, may be physiological, psychological, sociocultural, developmental,
or spiritual (Neuman & Fawcett, 2011). Neuman views individuals as possessing a core
structure that is safeguarded by lines of resistance. An individual’s level of health is
determined by well-functioning normal lines of defense (NLD; Neuman, 2011). If at any
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time, NLD becomes overtaxed, a flexible line of defense (FLD) protects it. Should the
FLD interact with an intense stressor, the system goes into a state of disequilibrium,
thereby becoming unstable (Neuman & Fawcett, 2011). As this occurs, lines of resistance
are activated, increasing the likelihood for the system to move into a state of illness. If the
system possesses adequate energy and support, it will re-stabilize and the NLD will be
restored to either its original state or improved from its previous state (Gonzalo, 2011).
The results of this study suggest that nurses and HCPs should first use medication
(a secondary prevention) to treat symptoms of OUD. Given the extent to which long-term
use of opioids can cause significant changes in the brain that impact affect, motivation,
and impulsivity, as well as result in a chronic disease process, a pharmacologic approach
is necessary. Once symptoms are relieved, the nurses intervene at the tertiary level to
strengthen lines of defense and lines of resistance that prevent stress from increasing the
risk of further harm due to relapse in an individual with OUD. At the tertiary prevention
level, the nurse or HCP assists an individual with OUD to adapt to an existence without
opioids (with counseling), to anticipate the likelihood and risk of relapse in order to
prevent it, and to return to a state of health and maintain it once the individual no longer
uses opioids. These study results support the use of both theoretical viewpoints as a basis
for providing care for OUD.
The aim of the study was to examine the impact of adding tertiary-preventionlevel variables (i.e., counseling) to secondary-prevention-level variables (medication
treatment with buprenorphine and naloxone) on several outcome variables. These include
medication utilization, treatment utilization, and substance use. The extent to which an
individual can successfully comply with and achieve treatment goals will determine
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whether successful adjustment to stress occurs. At the secondary prevention level,
medications such as Suboxone stabilize the neurobiological changes in the brain that
occurred due to OUD, so that adaption to the absence of opioids can take place. At the
tertiary prevention level, treatment utilization and counseling bolster one’s coping ability
in order to adapt to life without opioids. The result is improved health and stabilization.
Implications
As stated earlier, the findings of this study indicate that attending counseling
during treatment for OUD has minimal impact on treatment utilization, does not improve
medication utilization, and does not reduce opioid use. In examining this finding in the
context of studies done by other researchers, this has several implications for clinical
practice. First, while previous research suggests that intensive OUD treatment combined
with BUP and specific behavioral interventions (CBT, CM with escalating vouchers,
among others) are effective for many patients with OUD (Bickel et al., 2008; Christensen
et al., 2014), the present study did not find a meaningful relationship between counseling
and OUD treatment outcomes. Policy requiring OUD patients to attend “counseling” may
actually be harmful. As stated earlier, due to a lack of resources (monetary,
transportation, and childcare), some patients simply are unable to attend counseling.
Therefore, requiring counseling increases the risk of becoming a barrier to treatment, thus
reducing access to treatment. Requiring counseling restricts access, increases treatment
burden, and may not be necessary for all patients.
In addition, clinicians should pay attention to the unique needs of women in OUD
treatment. The findings of the present study suggest women are more likely to adhere to
medication treatment, yet test positive for benzodiazepines and amphetamines, a finding
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consistent with previous research (Back et al., 2011). Also, the women in this study had
higher rates of anxiety and PTSD/trauma than males. According to A. Campbell et al.
(2018), women are often prescribed anti-anxiety medications, which in turn increases
access and misuse (NIDA, 2018f). Clinicians should actively respond to the unique needs
of women in OUD treatment, including ensuring they receive treatment for anxiety, and
PTSD/trauma and anxiety. Further, they should identify the inappropriate use of
benzodiazepines and stimulants in women. Finally, clinicians must assist women to
address barriers to treatment and the potential stigma in seeking treatment.
The results of this study suggest that use of benzodiazepines and alcohol increases
with age. As mentioned earlier, the misuse of tranquilizers and sedatives has been
increasing among older adults in recent years and presents a number of significant
dangers associated with it (Olfson et al., 2015). This has occurred despite risks associated
with long-term benzodiazepine use. One major health risk associated with misuse of
sedatives and tranquilizers is suicidal ideation. Also, research suggests that
tranquilizer/sedative misuse has a unique pattern among older adults that has been largely
understudied (Schepis & McCabe, 2019).
Clinicians treating older adults for OUD and other chronic conditions should
screen older adults for misuse of benzodiazepines and sedatives given the health risks
these substances pose to this population. Given that older adults are at higher risk for
depression and suicide than other populations, and that misuse of these substances can
result in suicidal ideation, older adults must be carefully assessed for both. Further, they
should receive treatment for these problems along with other medical conditions.
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Lastly, given the importance of treatment utilization, medication adherence, and
treatment retention in preventing relapse of OUD, clinicians should actively work to
improve retention especially in office-based treatment and outpatient treatment centers
(Carroll & Weiss, 2017). Given that retention rates are about 50% in office-based OUD
treatment, and risk of relapse, overdose, and death are associated with dropout (Fiellin et
al., 2014), it is essential that clinicians work steadily toward increasing retention. In
addition, clinicians should continue to actively increase access to OUD treatment for
highly complex patients and those with co-occurring mental health disorders, chronic
medical problems as well as infectious diseases.
Implications for Nursing
An important implication for nurses who work with patients with OUD is to
utilize the most current evidence when formulating treatment plans. This is essential in
that present policies lack evidence that counseling is necessary even though it is
mandated by insurance companies and clinicians. By using evidence, patients have
increased chances of achieving treatment outcomes and not wasting time on ineffective
treatment models.
Also, nurses can have a unique role in reducing the misuse of prescription
opioids. According to the ANA (2018), nurses have an opportunity to lead the way in,
“an attitudinal transformation toward pain management.” (ANA, 2018, p. 2). The ANA
has commended steps put forth in The National Pain Strategy that focus on the following:
prevention, recognition, and intervention of pain issues in primary care settings; a personcentered interdisciplinary approach to pain management; and support for pain selfmanagement strategies (HHS, 2016). Since nurses are on the front lines of direct care,
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leadership, and executive roles, they are in pivotal positions to assist patients and families
weigh the risks and benefits of treatment options for pain. In the role of advocate and
educator, working closely with patients, they can encourage the use of non-opioid pain
management, such as other drug treatments, anesthetic interventions, surgery, counseling,
physical therapy, and complementary and alternative medical treatments (ANA, 2018).
Nurses, nurse practitioners (NPs), and HCPs must be active at the state level in
order to promote legislation being passed that lessens restrictions on the scope of practice
for NPs and reduces the significant shortage of professionals authorized to prescribe
medications for OUD. For example, six states in the United States with high levels of
opioid use have strong restrictions on NPs to prescribe medications that can significantly
help treat the problem (Maier, 2019). According to Spetz, Toretsky, Chapman, Phoenix,
and Tierney (2019), these states should reform their regulations in order to take full
advantage of the available workforce in addressing the opioid crisis. After examining
state-level data on the number of Drug Addiction Treatment Act waivers for physicians,
NPs, and physician assistants, they found the mean percentages of NPs with waivers was
5.58% in less restrictive states and 2.44% in more restrictive states. The researchers
suggest that if collaboration, supervision, and scope of practice restrictions cannot be
changed, states should work to connect NPs with physicians who are willing to supervise
them in treating patients with buprenorphine (Spetz et al., 2019).
For NPs who do prescribe medications for OUD, several steps can be taken to
address prescription opioid use by improving safe and appropriate prescribing. (ANA,
2018). The steps include improving clinical education and decision making to reduce
inappropriate prescribing; increase prescription monitoring and health information
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technology to support proper pain management; and utilizing best practices to increase
safe prescribing.
Finally, the International Nurses Society on Addictions (IntNSA), an organization
dedicated to improving the well-being of individuals and families impacted by substance
use, recently worked to outline a plan for increasing opportunities for nurses around the
globe to collaborate in order to improve the response to addiction at all levels. In this
way, it is now possible for the membership to effect change and improve treatment at
local, organizational, national, regional, and international levels (Clancy & Fornili, 2019).
Limitations
There were several limitations to this research. First, given the data was derived
from an EHR, there was a lack of control over its integrity. Secondly, HCPs are subject to
human error when documenting patients’ history and assessment findings, which could
have affected the reliability and validity of the data, limiting the generalizability of the
findings. In addition, during the data collection process, there was the risk of interviewer
bias affecting the validity of data collected.
Another concern was the reliability of patient-reported data. Analysis of the data
suggested there was a significant difference between patient-reported counseling and data
that was based on confirmatory scans of current and prior counseling. Of patients who
reported receiving counseling, only 39.1% had confirmation scans of current counseling.
Among patients who reported receiving counseling, only 40.2% had confirmatory scans
of prior counseling.
Also, patients treated at the centers in this study likely had either insurance or
monetary resources, which limits generalizability of the findings. In addition, there was a
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lack of racial and ethnic diversity in the study sample, limiting generalizability of
findings to populations vulnerable to OUD and those least likely to get treatment. Other
limitations included the requirements for participating in treatment, namely
transportation. Additionally, the study examined patients who took one type of
medication, and who were from a nonrandomized sample. Another important limitation
was that patients were required to attend counseling as part of the treatment protocol. The
result may support the addition of counseling in the analyses.
Questions for Future Research
The results of this study pose several areas for future research. In this study,
counseling during treatment for OUD had minimal impact on treatment utilization and no
impact on medication utilization or opioid use, two key outcomes of treatment. However,
previously attending counseling at some point in treatment did have a positive impact on
medication adherence, reduced opioid use and cocaine use. Research examining the
underlying mechanisms for this difference would be useful. This understanding may also
assist in the identification of specific patient populations for whom counseling is
beneficial, and patient populations who do not benefit from counseling while in OUD
treatment. Additional research on improving retention in office-based treatment is
necessary given the high attrition rates after 6 months. Studies that examine the benefits
of utilizing functional outcomes as indicators of treatment response, as opposed to
retention and urine screens alone, could widen measures and definitions of treatment
success in OUD treatment. Also needed are studies on subgroups of patients who are
more likely to benefit from combinations of treatment such as those with more severe
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opioid use, complex patients, and patients with co-occurring mental health conditions,
medical diseases, and infectious diseases.
Future research should focus on the unique needs of women in OUD treatment,
especially those with anxiety, PTSD/trauma, other co-occurring conditions and reduced
access to care. Also, exploring ways to increase access to the best choice of medication
treatment for OUD regardless of ethnicity, race, and ability to pay is needed. Finally,
additional research on the misuse of benzodiazepines and alcohol among older adults
would be beneficial since this problem has recently increased, and has a unique pattern
and dangerous health consequences.
Conclusion
The purpose of this research was to examine the impact of psychosocial
treatment, specifically counseling, on medication utilization, treatment utilization, opioid
use, and treatment retention in patients who had received treatment for OUD. Current
counseling attendance did not have a significant impact on treatment utilization,
medication utilization, or drug use. Although current counseling was not significant,
counseling at some point in treatment had a positive impact on treatment utilization and
medication utilization and reduced both cocaine use and opioid use. It may be that
counseling is also more important for some patients than others. This finding should be
examined in future research.
Current practice for most treatment programs is to require all patients in treatment
for OUD to attend counseling in order to stay in treatment. This requirement is
potentially harmful in that it is not evidence based and may result in premature discharge
from treatment and additional hardship for patients. Additionally, lack of resources
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(monetary, transportation, childcare) and a high number of touchpoints during care
preclude some patients from attending counseling. This in turn presents a potentially
harmful barrier and thus reduces access to treatment for those who need it.
Additionally, clinicians should work actively to meet the needs of special
populations in OUD treatment such as women, older adults, and patients with cooccurring mental health disorders, chronic illnesses, and infectious diseases. Also, given
the importance of treatment utilization, medication adherence, and treatment retention in
preventing relapse of OUD, clinicians should actively work to improve retention in care
and reduce the patient treatment burden.
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